REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Whole Live Micro-organism, Cell, Or Virus Containing > Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.)Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070190032 - Use of local immune suppression to enhance oncolytic viral therapy Provided herein are methods for treating or ameliorating a solid tumor in a subject comprising administering oncolytic viruses and immunosuppressive agents at or near the site of the tumor. ... 08/16/07 - 20070190031 - Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv The invention provides a DNA plasmid comprising: (a) a first transcriptional unit comprising a nucleotide sequence that encodes a first polypeptide operably linked to regulatory elements including a first promoter and a first polyadenylation signal; (b) a second transcriptional unit comprising a nucleotide sequence that encodes a second polypeptide operably ... 08/16/07 - 20070190030 - Method of treating arthritis using lentiviral vectors in gene therapy Novel methods for treating and preventing arthritis, such as rheumatoid arthritis, are disclosed which employ lentiviral gene delivery vectors, including HIV-based lentiviral vectors, to deliver a therapeutic gene to a subject. Lentiviral-based vectors treat arthritis by promoting high-level expression of the transferred therapeutic gene in the target tissue of the ... 08/16/07 - 20070190029 - Listeria-induced immunorecruitment and activation, and methods of use thereof Provided are reagents and methods for administering an attenuated bacterium for use in treating a cancerous or infectious condition. Reagents and methods for administering an attenuated bacterium for use in inducing an immune response against a tumor, cancer cell, or infective agent are further provided. Also provided are methods of ... 08/16/07 - 20070190028 - Method and apparatus for heat or electromagnetic control of gene expression A gene regulatory system controls biomarker, gene therapy or endogenous gene expression by emitting one or more forms of energy that regulate gene expression. The system may include a sensor to sense a signal indicative of a need for therapy. The regulation of gene expression is controlled based on the ... 08/16/07 - 20070190027 - Targeting of herpes simplex virus to specific receptors The invention relates to engineered Herpes simplex virus (HSV) particles that are targeted to one or more specific binding pair members, such as receptors. Also, recombinant vectors for producing such HSV particles are provided. By reducing the affinity of HSV for its natural receptor(s) and increasing the affinity for a ... 08/09/07 - 20070184028 - Conditional gene vectors regulated in cis The present invention is directed to a conditional gene vector system and to a host cell, which has been transfected with such a vector system. The present invention is further directed to a combined preparation comprising the vector system of the invention and an interfering agent. Furthermore, a pharmaceutical composition ... 08/09/07 - 20070184027 - Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases The present invention relates to methods and compositions for treatment of cardiovascular and peripheral vascular diseases using ex vivo and in vivo gene delivery technologies. One aspect of the present invention relates to a method for treating a vascular disease by introducing a DNA sequence encoding a TM protein or ... 08/09/07 - 20070184026 - Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring ... 08/09/07 - 20070184025 - Chimaeric vector system This invention relates to a process for producing a Simian Immunodeficiency Virus (SIV) encoding a heterologous gene, which process comprises infecting a host cell with a first vector which is capable of producing SIV capsid and a second vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal sufficient ... 08/02/07 - 20070178069 - Herpes simplex virus vector The invention provides a herpes simplex virus vector comprising deletions in ICP4, ICP27, and UL55. ... 08/02/07 - 20070178068 - Compositions and methods for regulating complement system The disclosure provided herein provides for methods and compositions for modulating the human complement pathway by reducing the expression or production of one or more complement pathway protein and uses for such methods for treating diseases including ocular disease and macular degeneration related disease. The invention also includes active agents ... 08/02/07 - 20070178067 - System and method for cytological analysis by raman spectroscopic imaging A method and system of differentially manipulating cells where the cells, suspended in a fluid, are irradiated with substantially monochromatic light. A Raman data set is obtained from the irradiated cells and where the data set is characteristic of a disease status. The data set is assessed to identify diseased ... 08/02/07 - 20070178066 - Pathotropic targeted gene delivery system for cancer and other disorders Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as ... 08/02/07 - 20070178065 - Neutralizing factors as vaccine adjuvants The present invention is a vaccine adjuvant composed of a vaccinia virus vector that encodes a polypeptides capable of neutralizing immune suppressive factors thereby enhancing or stimulating an immune response to a vaccine. ... 08/02/07 - 20070178064 - Antisense iap nucleobase oligomers and uses thereof The present invention features nucleobase oligomers that hybridize to IAP polynucleotides, and methods for using them to enhance apoptosis and treat proliferative diseases. ... 07/26/07 - 20070172462 - Sirna-mediated gene silencing of synuclein The present invention is directed to small interfering RNAs that down regulate expression of a synuclein gene and methods of using the small interfering RNAs. ... 07/26/07 - 20070172461 - Polyepitope vaccines The present invention relates to a recombinant polyepitope cytotoxic T lymphocyte vaccine. The vaccine comprises at least one recombinant protein including a plurality of cytotoxic T lymphocyte epitopes from one or more pathogens, wherein the at least one recombinant protein is substantially free of sequences naturally found to flank the ... 07/26/07 - 20070172460 - Random peptide library displayed on aav vectors Described is a method of producing a repertoire of random peptides on the surface of AAV particles wherein said random peptides are expressed as a fusion with an AAV capsid protein of an AAV particle which displays at its surface said random polypeptides. Also described is a peptide library obtainable ... 07/19/07 - 20070166286 - Self-rearranging dna vectors Disclosed are replicatable viral DNA vectors encoding a site-specific DNA-altering enzyme and a DNA target recognized by the enzyme, the enzyme selectively converting, in a cell expressing the enzyme, the DNA vector to a rearranged form. The invention further relates to methods for assembling recombinant adenoviral DNAs. These methods include ... 07/19/07 - 20070166285 - Systems and methods related to degradation of uremic toxins The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects ... 07/19/07 - 20070166284 - Therapeutic regimen for treating cancer The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about ... 07/19/07 - 20070166283 - Compositions and methods for the treatment of hemophilia a Improved materials and methods for the treatment of Hemophilia A are provided. ... 07/12/07 - 20070160581 - Production of ssdna in vivo Methods and compositions comprising a DNA expression cassette for producing ss-cDNA inside a host cell (in vivo). The expression system optionally contains a reverse transcriptase/RNAse H coding gene, and a restriction endonuclease gene. The cassette carries cloning sites in two distinct locations for cloning and expressing a sequence of interest. ... 07/05/07 - 20070154458 - Combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector A composition of matter comprising a vaccinia virus expression vector with a negative thymidine kinase phenotype and a negative vaccinia virus growth factor phenotype. ... 07/05/07 - 20070154457 - Use of eif-5a to kill multiple myeloma cells The present invention relates to eucaryotic initiation factor 5A and the use of polynucleotides encoding the same to inhibit cancer cell growth and inhibit metastases. In a preferred embodiment, eIF-5A1 is used to kill multiple myeloma cells. ... 07/05/07 - 20070154456 - Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression Disclosed are genetic expression cassettes, and vector comprising them useful for the delivery of nucleic acid segments encoding selected therapeutic constructs (including for example, peptides, polypeptides, ribozymes, and catalytic RN molecules), to selected cells and tissues of vertebrate animals. The disclosed genetic constructs are useful in the development of gene ... 07/05/07 - 20070154455 - Monoparamunity inducers based on attenuated rabbit myxoma viruses The invention relates to monoparamunity inducers that are based on paramunizing viruses or viral components of a myxoma virus strain of diseased rabbits that show general symptoms of the disease. The invention also relates to a method for producing the inducers and to their use as drugs for the regulatory ... 06/28/07 - 20070148134 - Potent inhibition of influenza virus by specifically designed short interfering rna said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a ... // - 3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′ - ... // - 5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAG 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCdTdT 3′ - ... 06/28/07 - 20070148133 - Potent inhibition of influenza virus by specifically designed short interfering rna said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a ... // - 3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′ - ... // - 5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAG 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCdTdT 3′ - ... 06/28/07 - 20070148132 - Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system A vector and a method are provided for delivering a nucleic acid to a nervous system cell. The vector includes a first nucleic acid, a second nucleic acid, inverted terminal repeats of adeno-associated virus, and a tetracycline-off regulatable promoter system that includes a first promoter operably linked to the first ... 06/21/07 - 20070141030 - Targeted pre-mrna/mrna modification and gene regulation Methods for affecting mRNA expression or translation through the modification of pre-mRNA or mRNA transcripts are described. In one embodiment of the methods of the present invention, the branch point adenosine of a pre-mRNA transcript is 2′-O-methylated to block splicing and subsequent expression of the protein encoded by the transcript. ... 06/21/07 - 20070141029 - Methods of gene therapy for treating disorders of the ear by adminstering a vector encoding an antonal-associated factor The invention is directed to a method of changing the sensory perception of an animal. The method comprises administering an expression vector comprising a nucleic acid sequence encoding an atonal-associated factor, which is expressed to produce the atonal-associated factor resulting in generation of hair cells that allow perception of stimuli ... 06/21/07 - 20070141028 - Cancer gene therapeutic drug A cancer gene therapeutic drug of the present invention includes a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from A549 cell, 293 cell, SW626 cell and ... 06/21/07 - 20070141027 - Non-lethal conditioning methods for conditioning a recipient for bone marrow transplantation Mixed chimerism induces donor-specific transplantation tolerance to organ allografts. Strategies to establish mixed chimerism using partial conditioning having significantly reduced the morbidity associated with conditioning. The donor hematopoietic cell lineage(s) responsible for the induction and subsequent maintenance of tolerance in partially conditioned recipients are not defined at present. As one ... 06/14/07 - 20070134206 - Targeting proteins to deliver therapeutic or diagnostic reagents The present invention is directed to compositions comprising an angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a specific embodiment, the composition is a fusion gene or fusion gene product encoding the angiogenesis inhibitor coupled to a therapeutic or diagnostic agent. In a particular embodiment, the composition is ... 06/14/07 - 20070134205 - Gene delivery of detoxifying agent Gene delivery of a detoxifying agent is described. ... 06/14/07 - 20070134204 - Method for treating nerve injury and vector construct for the same A method is provided for treating a nerve injury, including steps of: transforming the nerve injury site with a gene coding for an acid fibroblast growth factor (aFEF); and allowing the gene to be expressed at the nerve injury site. Also provided is a vector for use in the method. ... 06/14/07 - 20070134203 - Compositions and methods for increasing packaging and yields of recombinant adenoviruses using multiple packaging signals A recombinant adenoviral vector which has multiple adenovirus packaging domains is provided. This vector has advantages over conventional adenoviral vectors in packaging plasmid vectors into adenoviral capsids. Methods of making and using this vector are described. ... 06/14/07 - 20070134202 - Cancer gene therapeutic drug A cancer gene therapeutic drug of the present invention comprises a combination of: a virus for immunological treatment to be administered for inducing a CTL reaction within a living body to administration of a carrier cell; and a carrier cell to be infected with an oncolytic virus before the administration ... 06/14/07 - 20070134201 - Archaeon expression system The present invention relates to a sulfolobus expression vector comprising: (a) sulfolobus origin of replication; (b) the genes encoding the structural proteins and the site-specific integrase of SSV1, SSV2 or pSSVx, operatively linked to expression control sequences and a packaging signal; (c) one or more selectable marker gene(s), operatively linked ... 06/14/07 - 20070134200 - Immunogenic composition and methods A method of inducing an antigen-specific immune response in a mammalian subject includes the steps of administering to the subject an effective amount of a first composition comprising a DNA plasmid comprising a DNA sequence encoding an antigen under the control of regulatory sequences directing expression thereof in a mammalian ... 06/07/07 - 20070128169 - Inhibition of gene expression by delivery of polynucleotides to animal cells in vivo Described is a process for intravascular delivery of a polynucleotide to an extravascular cell of a mammal to inhibit gene expression. A polynucleotide containing sequence that is similar to a sequence in the gene to be expressed is made and inserted into a vessel in the mammal. The polynucleotide is ... 06/07/07 - 20070128168 - Novel genes regulated in the developing human ventral mesencephalon A human embryonal stem cell, neural stem cell, neural precursor cell, neural cell or dopaminergic neuron is genetically modified to overexpress at least one of certain genes identified as regulated in the developing human ventral mesencephalon, and more particularly, up-regulated in the ventral tegmentum. The genes are associated with dopaminergic ... 06/07/07 - 20070128167 - Complexing agents for compositions containing inclusion complexes The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent. The polymer interacts with the complexing agent in a host-guest or a guest-host interaction to form an inclusion complex. A therapeutic composition of the invention may be used ... 06/07/07 - 20070128166 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 06/07/07 - 20070128165 - Recombinase-based system for expression of foreign proteins using adenovirus vectors In the present invention, viruses, plasmids or both are constructed which contain viral DNA and lox sites positioned such that site-specific recombination between lox sites in separate plasmids results in generation of infectious viral DNA at high-efficiency in cotransfected host cells that have been engineered to express the Cre recombinase. ... 06/07/07 - 20070128164 - Polypeptide The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use ... 06/07/07 - 20070128163 - Adeno-associated virus-mediated delivery of angiogenic factors The use of recombinant adeno-associated virus (rAAV) virions for delivery of genes encoding angiogenic factors to muscle tissue is disclosed. The invention describes such methods of delivery and also describes methods for treating an ischemic condition such as myocardial ischemia. The methods include direct delivery of rAAV virions to a ... 05/31/07 - 20070122385 - Replication competent viruses capable of silencing virus inhibitory factor expression Described is a replication-competent virus capable of replication and having lytic capacity in target cells. The virus comprises in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the target cells, operably linked to one or more ... 05/24/07 - 20070116673 - Method for activating t cell protein phosphatase and therapeutical methods based thereon This invention relates to methods for activation of T cell protein tyrosine phosphatase (TCPTP) and for inhibiting tyrosine kinase signalling in an individual. The invention concerns a method for preventing or treating a disease or disorder in an individual, wherein said disease or disorder is curable by inhibiting tyrosine kinase ... 05/24/07 - 20070116672 - Treatment of rheumatic diseases The present invention relates to the treatment of rheumatic diseases with a vaccinia virus complement control protein (VCP). ... 05/24/07 - 20070116671 - Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides The invention relates to immobilized or encapsulated enzyme and/or cells to lower bile acids and cholesterol. The invention also relates to methods of quantitatively measuring bile acids. The invention provides a composition for decreasing the amount of a target compound in the gastrointestinal tract of an animal, comprising: a) a ... 05/24/07 - 20070116670 - Use of the adenoviral e2 promoter The invention relates to a nucleic acid construct comprising an adenoviral E2 late promoter or a fragment thereof and a nucleic acid. The nucleic acid is selected from the group of transgenes, genes and nucleic acids which are respectively different from adenoviral nucleic acid controlled by an E2 late promoter. ... 05/17/07 - 20070110724 - Duplexed parvovirus vectors The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the ... 05/17/07 - 20070110723 - Delivery of trefoil peptides The present invention relates to a microorganism, preferably a bacterial strain, preferably a non-pathogenic strain, preferably a non-invasive strain, preferably a food grade strain, preferably a gram-positive bacterial strain, delivering a trefoil peptide in vivo. Preferably said trefoil peptide is TFF1. The present invention further relates to a method for ... 05/17/07 - 20070110722 - Methods and compositions for the synthesis of rna and dna Methods for the production of duplexes and single-stranded RNA and/or DNA of a desired length and sequence based on a novel template design which incorporates 2 polymerase promoters, primers, and production sequences within a single molecule are provided. This Single-stranded Template molecule design allows high-efficiency, high-yield production of single or ... 05/17/07 - 20070110721 - Plasmid maintenance The invention relates to a system for stable maintenance of a plasmid, to host cells for use in this system and to methods of using the system to obtain a plasmid useful in medical applications. In particular, the invention provides transformed host cell containing: i) a chromosomal gene which inhibits ... 05/17/07 - 20070110720 - Vectors, mutant viruses and methods for generating mutant viruses A nucleic acid vector comprising first and second nucleotide sequences corresponding to nucleotide sequences flanking an insertion site in the genome of a selected herpes simplex virus strain; and a cassette located between said first and second nucleotide sequences comprising nucleic acid encoding: (a) one or a plurality of insertion ... 05/17/07 - 20070110719 - Novel use of adenoviruses and nucleic acids that code for said viruses The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene ... 05/17/07 - 20070110718 - System for treating and preventing breast cancer The present invention is directed to a system for treating individuals at risk of or suffering from breast cancer. The system comprises administering to the individual a recombinant poxvirus, where the poxvirus contains in a foreign nucleic acid encoding at least one breast cancer antigen. ... 05/17/07 - 20070110717 - Dna vaccines against tumor growth and methods of use thereof A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated ... 05/17/07 - 20070110716 - Relationship of a specific metabolite to insulin resistance Provided are methods and reagents for reducing ketone levels (for example, β-hydroxybutyrate) in skeletal muscle. Also provided are methods and reagents for treating insulin resistant states, such as diabetes. Further provided are screening methods for identifying compounds to reduce skeletal muscle ketone levels and/or to treat insulin resistance, for example, ... 05/10/07 - 20070104690 - Retroviral vectors Retroviral vector production systems for producing lentivirus-based vector particles which are capable of infecting and transducing non-dividing target cells, wherein one or more of the auxiliary genes such as vpr, vif, tat, and nef in the case of HIV-1 are absent, from the system. The systems and resulting retrovirus vector ... 05/10/07 - 20070104689 - Compositions and methods for treating tumors presenting survivin antigens The present invention provides compositions and methods that elicit an immune response against diseased cells. In particular, the present invention provides compositions and methods for the presentation of a peptide related to survivin on antigen-presenting cells. Presentation of the peptide leads to an immune response in a mammal against cells ... 05/10/07 - 20070104688 - Small interfering rna mediated transcriptional gene silencing in mammalian cells The present invention relates to transcriptional gene silencing (TGS) in mammalian, including human, cells that is mediated by small interfering RNA (siRNA) molecules. The present invention also relates to a method for directing histone and/or DNA methylation in mammalian, including human, cells. It has been found that siRNAs can be ... 05/10/07 - 20070104687 - Aav vectors for in vivo gene therapy of rheumatoid arthritis The present invention relates to the field of adeno-associated virus (AAV) based gene therapy, in particular in vivo gene therapy, of rheumatoid arthritis (RA). The invention provides recombinant AAV virions being highly efficient in delivering genes encoding therapeutic proteins to the arthritic joints, and method for using such virions in ... 05/10/07 - 20070104686 - Vaccines, immunotherapeutics and methods for using the same Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes an immunomodulator protein selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive ... 05/10/07 - 20070104685 - Synthetic gene encoding human carcinoembryonic antigen and uses thereof Synthetic polynucleotides encoding human carcinoembryonic antigen (CEA) are provided, the synthetic polynucleotides being codon-optimized for expression in a human cellular environment. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product ... 05/10/07 - 20070104684 - Ocular gene therapy Methods are provided for the treatment of choroidal neovascularization by increasing, in an individual afflicted with choroidal neovascularization, in vivo concentrations of an endostatin protein in the ocular tissues of the individual to a choroidal neovascularization inhibiting effective amount, where the endostatin protein has anti-choroidal neovascularization activity in vivo. ... 05/03/07 - 20070098692 - Materials and methods for treating ocular-related disorders The present invention is directed to a method of prophylactically or therapeutically treating an animal for at least one ocular-related disorder, e.g., ocular neovascularization or age-related macular degeneration. The method comprises contacting an ocular cell with an expression vector comprising a nucleic acid sequence encoding an inhibitor of angiogenesis and ... 05/03/07 - 20070098691 - Prostate specific antigen oligo-epitope peptide The invention is a prostate specific antigen oligo-epitope peptide which comprises more than one PSA epitope peptide, which conforms to one or more human HLA class I motifs. The prostate specific antigen oligo-epitope peptide in combination with various HLA-class I molecules or interactions with various T-cell receptors elicits PSA specific ... 05/03/07 - 20070098690 - Truncated cmv promoters and vectors containing same The present invention relates to nucleic acid molecules comprising certain truncated forms of the human cytomegalovirus (CMV) immediate-early enhancer-promoter, either alone or operably linked to transgenes of interest, including those encoding partially-deleted CFTR proteins. This invention further relates to vectors comprising these nucleic acid molecules and host cells transformed by ... 05/03/07 - 20070098689 - Mutant viruses An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy. ... 04/26/07 - 20070092490 - High efficiency sin vector The present application discloses viral vector that includes the following elements: (1) a promoter in U3 region of MSV 5′LTR; (2) repeating unit of MSV 5′LTR; (3) U5 region of MSV 5′LTR; (4) packaging signal; (5) a promoter; (6) internal ribosome entry site (IRES); (7) defective MLV 3′ LTR; (8) ... 04/26/07 - 20070092489 - Use of receptor sequences for immobilizing gene vectors on surfaces The present invention relates to compositions and methods of immobilizing a viral vector to an implantable medical device, for example a vascular stent. Specifically, a composition for delivery of a therapeutic agent is provided which includes: a gene transfer vector, a surface and a modified protein, wherein the gene transfer ... 04/19/07 - 20070086985 - Vectors for tissue-specific replication The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per ... 04/19/07 - 20070086984 - Viruses for the treatment of cellular proliferative disorders Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, ... 04/19/07 - 20070086983 - Endothelium-targeting nanoparticle for reversing endothelial dysfunction The present invention includes delivery of isolated and purified nucleic acids that encode GTPCH proteins in nanoparticles for the treatment of endothelial cells damaged by diabetes, smoking, dyslipidemia, hypertension, and cardiovascular disease. The nanoparticles contain a nucleic acid sequence, polymer and a targeting ligand. The targeting ligand facilitates the selective ... 04/19/07 - 20070086982 - Gene therapy for regulating smooth muscle tone The present invention is directed towards a method of regulating smooth muscle tone, comprising the introduction, into smooth muscle cells of a subject, of a DNA sequence encoding a protein involved in the regulation of smooth muscle tone, and expression of the DNA sequence in a sufficient number of smooth ... 04/19/07 - 20070086981 - Delivery peptides, their constructs with active agents and use The present invention refers to delivery proteins, protein-cargo complexes, methods, and means for the enhanced delivery or transport of drugs, biologically active agents or other compounds as cargo or cargo molecules onto, into, or across biological membranes or tissues forming a biological barrier. ... 04/12/07 - 20070081978 - Adeno-associated virus-mediated survivin mutants and methods related thereto This invention provides two novel vectors, a vector comprising a rAAV-type 2 plasmid encoding mutant survivin (Cys84Ala), and a vector comprising a rAAV-type 2 plasmid encoding eGFP. This invention also provides compositions comprising the above vectors. This invention provides a method for inducing apoptosis in a cell comprising introducing into ... 04/12/07 - 20070081977 - Device for transdermal administration of active substances A device for transdermal administration of active substances, comprising a backing layer and an active substance-containing reservoir connected to the backing layer. The skin-facing contact surface of the device has a plurality of microprotrusions which are suitable for penetrating the skin and which are equipped with structures that make extracting ... 04/05/07 - 20070077234 - Regulation of t cell-mediated immunity by tryptophan A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in ... 04/05/07 - 20070077233 - Inhibition of pathological angiogenesis in vivo The present invention is directed to the inhibition of pathological angiogenesis in different tissues such as cancer, tumor, retinal or synovial tissue. It has been shown that over expression of RB2/p130 modulates the angiogenetic balance. It has been further shown that induction of RB2/p130 expression using a tetracycline-regulated gene expression ... 04/05/07 - 20070077232 - Conditioned cell culture medium compositions and methods of use Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal ... 04/05/07 - 20070077231 - Immune effector cells pre-infected with oncolytic virus Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect ... 04/05/07 - 20070077230 - Method for the pre-conditioning/fixation and treatment of diseases with heat activation/release with thermo-activated drugs and gene products A method of treating cancer by introducing heat into cancerous tissue and delivering a liposome containing an active agent or a thermo-activated drug, gene or virus to said tissue. The heat delivered is sufficient to release the active agent or activate the thermo-activated drug, gene or virus. The cancer can ... 04/05/07 - 20070077229 - Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a KLH1 haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well ... 04/05/07 - 20070077228 - Method of treating or retarding the development of blindness A method for treating an ocular disorder characterized by the defect or absence of a normal gene in the ocular cells of a human or animal subject involves administering to the subject by subretinal injection an effective amount of a recombinant adeno-associated virus carrying a nucleic acid sequence encoding the ... 04/05/07 - 20070077227 - Nucleic acid binding proteins The invention provides a method for designing a nucleic acid binding protein of the Cys2-His2 zinc finger class capable of binding to a nucleic acid quadruplet in a target nucleic acid sequence, wherein binding to base 4 of the quadruplet by an alpha-helical zinc finger nucleic acid binding motif in ... 04/05/07 - 20070077226 - Gutless adenovirus vector and the construction method thereof The present invention disclosed a kind of gutless adenovirus vector and the construction method thereof. Two structural independent but functional related cassettes, the trans-activator (TA) and anti-tumor cassette, are both carried by the gutless vector. hTERT promoter restricts the expression of TA only in tumor cells, and RU486, associated with ... 03/29/07 - 20070071726 - Recombinant viral-based malaria vaccines The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are ... 03/29/07 - 20070071725 - Nitric oxide synthase gene transfer This invention relates to to gene transfer, specifically, provided herein are methods, vectors and compositions for the transfer of nNOS gene affecting overexpression of nNOS in sympathetic and parasympathetic nervous system and its subsequent use in the treatment of related pathologies. ... 03/29/07 - 20070071724 - Methods for increasing learning and memory in amyloid-beta-related neurodegenerative disorders by increasing uch-l1 activity and methods for identifying enhancers of uch-l1 activity The invention is directed to methods for increasing learning and memory in a subject with a neuropathological condition, specifically a condition related to elevated beta-amyloid deposition, the method comprising administering to the subject an effective amount of a compound capable of increasing the activity of Uch-L1. The invention is also ... 03/29/07 - 20070071723 - In vivo enhancement of immune system recognition of neoplasms following treatment with an oncolytic virus or gene therapy vector This invention provides novel methods of treating or alleviating neoplasms and enhancing the efficacy of oncolytic viruses by administering an oncolytic virus to a mammal suffering from a neoplasm and subsequently administering an immunostimulant. The invention also provides methods of increasing immunorecognition of neoplastic cells. ... 03/29/07 - 20070071722 - Nucleotide vaccine composition The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises a nucleotide sequence encoding an antigenic molecule and gene-modified antigen-presenting ... 03/22/07 - 20070065412 - Production of recombinant aav using adenovirus comprising aav rep/cap genes This invention relates to novel adenoviruses useful in the production of high titers of recombinant adeno-associated virus (rAAV) comprising a foreign DNA inert and methods of making these adenoviruses. The adenovirus comprises the AAV rep gene in which the p5 promoter of rep is replaced by a minimal promoter or ... 03/22/07 - 20070065411 - Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF. ... 03/22/07 - 20070065410 - Peptides binding the phosphatase 2a protein and polynucleotides encoding same The invention relates to novel synthetic or natural E4orf4 or Bcl-2 peptides particularly useful in antitumoral, antiviral and antiparasitic treatments, said peptides being less than 30 amino acids long and binding in vitro to a phosphatase 2A protein holoenzyme or one of its subunits. The invention also relates to polynucleotides ... 03/22/07 - 20070065409 - Use of pleiotrophin in the diagnosis, treatment and prevention of disease Described herein are methods for transdifferentiating monocytes/macrophages into endothelial cells, based on the inventors' identification of pleiotrophin (“PTN”) as the gene responsible for this transdifferentiation. Further described are therapeutic methodologies for the promotion or inhibition of neovasculanization based on modulation of PTN. ... 03/22/07 - 20070065408 - Modified polypeptides for targeting cell-entry of the adenoviruses of subtype b This invention relates to modified polypeptides comprising two functional components: first, a polypeptide derived from the extracellular region of CD46 as a specific binding site for adenoviruses of the subgroup B, and second, a component capable of binding to a cell surface molecule. Such modified polypeptides are able to direct ... 03/15/07 - 20070059291 - Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (lcmv) The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy. ... 03/15/07 - 20070059290 - Transcriptional regulation of target genes The present invention describes a method of identifying inducible genetic regulatory sequences that can control the transcription of specific gene transcripts. Methods of using inducible genetic regulatory sequences are also discussed. In particular, the genetic regulatory sequences of the present invention can modulate the transcription of a nucleic acid transcript ... 03/15/07 - 20070059289 - Methods of improving cardiac function and attenuating and/or preventing cardiac remodeling with hsp20 Methods of improving cardiac function and/or methods for attenuating and/or prevention cardiac remodeling in an individual's heart comprising administering to an individual an effective amount of Heat-Shock Protein Hsp20 or an agent that increase the levels of and/or the activity of Hsp20 are provided. ... 03/15/07 - 20070059288 - Treatment for heart disease The present invention provides a system for treating heart disease using a combination of pro-angiogenesis therapy and cellular cardiomyoplasty. The system is particularly useful in treating patients with damaged myocardium due coronary artery disease, myocardial infarction, congestive heart failure, and ischemia. A pro-angiogenic factor (e.g., VEGF) or a means of ... 03/15/07 - 20070059287 - Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same The present invention relates to a transcriptional regulatory sequence with enhanced tumor-specificity and strength and a recombinant vector comprising the transcriptional regulatory sequence. More particularly, the present invention relates to a transcriptional regulatory sequence comprising a human telomere reverse transcriptase (hTERT) promoter linked to a nucleotide sequence that comprises one ... 03/15/07 - 20070059286 - Dna vaccines that express an adp-ribosyltransferase toxin devoid of adp-ribosyltransferase activity The present invention describes DNA vaccines that encode for and direct the coincident expression of an antigen and an ADP-ribosyltransferase toxin that is devoid of ADPribosyltransferase activity and methods for vaccinating animals with the same. The DNA vaccines are useful for vaccinating against viral, bacterial and parasitic pathogens. ... 03/08/07 - 20070053880 - Growth differentiation factor-16 Growth differentiation factor-16 (GDF-16) is disclosed along with its polynucleotide sequence and amino acid sequence Also disclosed are diganostic and therapeutic methods of using the GDF-16 polypeptide and polynucleotide sequences. ... 03/08/07 - 20070053879 - Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator Disclosed are full length isolated DNAs encoding cystic fibrosis transmembrane conductance regulator (CFTR) protein and a variety of mutants thereof. Also disclosed are antibodies specific for various CFTR domains and methods for their production. Expression of CFTR from cells transformed with these CFTR genes or cDNAs demonstrate surprising CFTR intracellular ... 03/01/07 - 20070048287 - Molecular antigen array The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array. The invention also provides a process for producing an antigen or antigenic determinant in an ordered and repetitive array. The ... 03/01/07 - 20070048286 - Method of treating dopaminergic and gaba-nergic disorders It is shown here that hedgehog proteins possess novel activities beyond phenotype specification. Using cultures derived from the embryonic day 14.5 (E14.5) rat ventral mesencephalon, we show that hedgehog is also trophic for dopaminergic neurons. Interestingly, hedgehog not only promotes dopaminergic neuron survival, but also promotes the survival of midbrain ... 03/01/07 - 20070048285 - Self-inactivating retroviral vector The invention relates to retroviral vectors, especially to self-inactivating (SIN) gammaretroviral or lentiviral vectors, suitable for producing viral particles at high titers, which can be used for efficient gene transfer into mammalian cells, organs or organisms, e.g. for gene therapy. More specifically, the present invention provides modified 5′-promoter elements in ... 03/01/07 - 20070048284 - Cardiac arrhythmia treatment methods Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. ... 03/01/07 - 20070048283 - Methods of inducing an immune response Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene ... 02/22/07 - 20070041947 - Use of a lentiviral vector in the treatment of pain Provided is a method for treating and/or preventing pain, in which a vector system is administered such that an EOI is delivered to a DRG of the subject. Also provided is a method for delivering an EOI to the spinal cord using such a vector system. Further provided is a ... 02/22/07 - 20070041946 - Serotype of adenovirus and uses thereof Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins ... 02/22/07 - 20070041945 - Novel method for down-regulation of amyloid A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal ... 02/22/07 - 20070041944 - Treating tumors by enh dislocation of id proteins The invention provides methods for the therapy of cancer that are directed towards preventing or inhibiting Id function. The present methods are based on contacting neoplastic or tumor cells with agents that can translocate an Id protein to the cytoplasm and/or sequester an Id protein in the cytoplasm, thereby preventing ... 02/22/07 - 20070041943 - Expression of virus entry inhibitors and recombinant aav thereof The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals. ... 02/22/07 - 20070041942 - Use of calcium binding proteins to improve cardiac contractile function Methods useful in the regulation of myocardial contraction are disclosed. The methods are useful in the regulation of heart function. The invention reveals that sorcin overexpression enhances cardiac contractile performance and establishes the concept of sorcin as a regulator of myocardial contractility. The invention also provides screening assays that allow ... 02/22/07 - 20070041941 - Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same Fusion proteins and nucleic acid molecules encoding fusion proteins are disclosed. Fusion proteins comprising non-IL-15 signal peptide linked to IL-15 protein sequences and fusion proteins comprising an IgE signal peptide linked to non-IgE protein sequences are disclosed. Vectors comprising such nucleic acid molecules; and to host cells comprising such vectors ... 02/15/07 - 20070036764 - Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr Novel methods and compositions for selective killing of cells by activation of PKR are disclosed. In a preferred embodiment, a method is provided for causing cell death in a targeted population of cells that includes the steps of: selecting a nucleotide sequence at a single genetic locus in the targeted ... 02/15/07 - 20070036763 - Interleukin-17 receptor homologue Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.” ... 02/15/07 - 20070036762 - Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer A novel gene (designated 85P1B3) and its encoded protein are described. While 85P1B3 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in multiple cancers including set forth in Table 1. Consequently, 85P1B3 provides a diagnostic and/or therapeutic target for cancers. The 85P1B3 gene or fragment thereof, ... 02/15/07 - 20070036761 - Lentiviral apoe2 gene therapy The present invention is a method for inhibiting or reducing disease progression in subjects suffering from conditions or diseases related to the Aβ peptide, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like. The method comprises admininstering an apoE2 lentiviral vector to the subject. ... 02/15/07 - 20070036760 - Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided. ... 02/15/07 - 20070036759 - Method of preparing a proliferation-regulated recombinant adenoviral vector efficiently and kit for preparing the same Provided is a method of preparing a proliferation-regulated recombinant adenoviral vector effectively, comprising preparing a proliferation-regulated vector plasmid by preparing a restriction enzyme-recognizing sequence in a vector plasmid having a proliferation-regulating unit and having an E1A region, a protein-coding region in a E1B region, a poly(A) signal sequence, and a ... 02/15/07 - 20070036758 - Mutants of vaccinia virus as oncolytic agents The present invention relates to mutant oncolytic vaccinia viruses and their use for selective destruction of cancer cells. The mutant vaccinia viruses of the invention include those having a reduced ability to inhibit the antiviral dsR-NA dependent protein kinase (PKR) and increased sensitivity to interferon. Such mutants include, for example, ... 02/15/07 - 20070036757 - Aav vector for gene therapy Described are recombinant AAV vectors characterized in that they carry capsid protein modification(s) resulting in a reduced or eliminated heparin binding function. The AAV vectors of the present invention are particularly suitable for gene therapy by systemic application, since (a) transduction of the liver is eliminated or at least drastically ... 02/15/07 - 20070036756 - Method for treating ischemic diseases The present invention provides methods for treating ischemic diseases, which comprise the step of administering angiopoietin-1 (Ang1) or an Ang1-encoding vector. The present invention also provides ischemic disease treatment kits which comprise Ang1. Ang1-expressing vectors were prepared, and each was administered alone intramyocardially to rats in the acute phase of ... 02/08/07 - 20070031383 - Recombinant herpes simplex virus useful for treating neoplastic disease Recombinant herpes simplex viruses comprising DNA encoding cytokines and methods for treating neoplastic diseases using the inventive recombinant viruses are disclosed. ... 02/08/07 - 20070031382 - Method for introducing and expressing genes in animal cells, and live invasive bacterial vectors for use in the same A method for introducing and expressing genes in animal cells is disclosed comprising infecting the animal cells with live invasive bacteria, wherein the bacteria contain a eukaryotic expression cassette encoding the gene. The gene may encode, e.g., a vaccine antigen, a therapeutic agent, an immunoregulatory agent or an anti-sense RNA ... 02/08/07 - 20070031381 - Recombinant adenoviral vector and method of use This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 02/08/07 - 20070031380 - Integration-site directed vector systems Some aspects of the application describe materials and methods for making a molecular tether. A molecular tether, in certain embodiments, includes a target-DNA-binding domain having a specific binding affinity for a target-DNA segment in a host chromosome, a carrier-binding domain that specifically binds to a DNA segment on a carrier, ... 02/08/07 - 20070031379 - Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same The present invention relates to an anticancer or an anti-metastatic agent for gene therapy, more precisely, an anticancer or an anti-metastatic agent for gene therapy containing a gene carrier or cells harboring human apolipoprotein (a) kringle KIV9-KIV10-KV (LK68) or KV (LK8) gene as an effective ingredient, and a treatment method ... 02/08/07 - 20070031378 - Minicircle vector production A plasmid is provided comprising comprising the following functional units: a prokaryotic origin of replication, a marker sequence, two specific recombinase recognition sequences and a multiple cloning site, whereby it comprises a gene coding for a sequence specific recombinase, whereby the units are arranged on the plasmid in such a ... 02/01/07 - 20070025971 - Substances causing differentiation A DNA construct is described which contains a fusion gene under the control of a promoter. The fusion gene comprises at least one resistance gene and at least one reporter gene and is slightly toxic to a host cell transfected with that DNA construct. That DNA construct can be encoded ... 02/01/07 - 20070025970 - Vector system The present invention relates to retroviral vector genomes and to vector systems comprising such genomes. In particular the present invention relates to a retroviral vector genome comprising two or more NOIs operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs ... 02/01/07 - 20070025969 - Rnai expression constructs The present invention provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues or organs of interest in vitro and in vivo so as to treat diseases or disorders. ... 02/01/07 - 20070025968 - Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes The present invention relates to the field of molecular biology and immunology. In particular it relates to vaccines and methods for providing vaccines which elicit immune responses when administered to a mammal, in particular a human. The preferred elicited immune response is a T cell response, elicited by peptide T ... 02/01/07 - 20070025967 - Zap protein and related compositions and methods This invention provides an isolated ZAP protein and methods and articles of manufacture for increasing resistance to a virus in a subject or mammalian cell. The instant methods and articles are based on the use the ZAP protein to increase such resistance to a virus. ... 01/25/07 - 20070020239 - Heximi as a suppressor of hiv replication and cardiac hypertrophy Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding. ... 01/25/07 - 20070020238 - Method of targeted gene delivery using viral vectors Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic ... 01/25/07 - 20070020237 - Glucose inducible insulin expression and methods of treating diabetes The invention provides an isolated tissue specific glucose responsive promoter having a polymerase binding domain 3′ to at least one tripartite transcription factor binding cis element having a hepatocyte nuclear factor-1 (HNF-1) element, a CAAT/enhancer binding protein (C/EBP) response element and a glucose-response element (GRE). The promoter can include a ... 01/25/07 - 20070020236 - Defective sindbis viral vectors Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for ... 01/18/07 - 20070014769 - Adenovirus vectors comprising meganuclease-type endonucleases, and related systems The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or ... 01/18/07 - 20070014768 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition ... 01/18/07 - 20070014767 - Tgfbeta1-inhibitor peptides Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment ... 01/18/07 - 20070014766 - Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof The present invention provides methods for promoting generation of heart tissue, and for treating and preventing heurt tissue degeneration. Additionally, the present invention provides a therapeutic composition comprising a cyclin-associated agent, and a kit comprising the composition. The present invention further provides a heart tissue tell, a sidepopulation progenitor tell, ... 01/11/07 - 20070009488 - Feline granulocyte macrophage colony stimulating factor nucleic acid molecules The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine ... 01/11/07 - 20070009487 - Minimal promoters and uses thereof Minimal promoter sequences are described. Reagents including a nucleic acid molecule which contains these minimal promoter sequences are also described. Methods for constructing these reagents, and methods for using these reagents are also described. ... 01/11/07 - 20070009486 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 01/11/07 - 20070009485 - Nucleic acid delivery The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods ... 01/11/07 - 20070009484 - Compositions and methods involving mda-7 for the treatment of cancer The present invention concerns methods and compositions involving MDA-7 protein or an MDA-7-encoding nucleic acid in combination with either 1) a COX-2 selective inhibitor, such as celecoxib, 2) an Hsp90 inhibitor, such as geldanamycin, or a geldanamycin derivative or analog, 3) a vitamin E compound, for the treatment of cancer, ... 01/11/07 - 20070009483 - Compositions and methods for the therapeutic treatment of diabetes The invention provides a vector having a nucleic acid operably linking a promoter, an intron, a secretory leader sequence encoding nucleic acid, a human betacellulin (BTC) encoding nucleic acid, or functional fragment thereof, and a polyadenylation signal sequence, wherein expression of BTC produces a secreted, mature BTC. Also provided is ... 01/11/07 - 20070009482 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 01/11/07 - 20070009481 - Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis The present invention is related to the use of an adeno-associated virus, whereby the adeno-associated virus comprises a) FRNK or a derivative thereof, or b) a nucleic acid encoding FRNK or a derivative thereof, or of a nucleic acid coding for an adeno-associated virus, whereby the nucleic acid comprises a ... 01/04/07 - 20070003524 - Targeted retrograde gene delivery to motor neurons Methods are disclosed for delivering a heterologous gene to a cell body of a neuron by contacting a muscle tissue innervated by the neuron with a viral vector comprising a heterologous gene, wherein the viral vector enters said neuron and is retrogradely moved to the cell body. Additionally, methods for ... 01/04/07 - 20070003523 - Compositions and methods for sirna inhibition of angiogenesis RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types ... 01/04/07 - 20070003522 - Methods and compositions for improved retroviral gene and drug delivery The present invention provides recombinant viral particles for gene therapy and liposome compositions for drug delivery comprising an env protein of MMTV. The invention also provides retroviral or lentiviral env proteins comprising a mutation in a receptor-binding motif. The invention also provides nucleic acids, proteins, and compositions comprising the recombinant ... 01/04/07 - 20070003521 - Expression vectors containing hybrid ubiquitin promoters Sustained transgene expression will be required for the vast majority of genetic diseases being considered for gene therapy. The initially high levels of expression attained with plasmid DNA (pDNA) vectors containing viral promoters, such as that from cytomegalovirus (CMV), decline precipitously to near background levels within 2 to 3 weeks. ... 01/04/07 - 20070003520 - Mutant viruses An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of ... 01/04/07 - 20070003519 - Targets for tumor growth inhibition The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that ... 01/04/07 - 20070003518 - Raav vector-based compositions and methods for the prevention and treatment of mammalian diseases Disclosed are recombinant adeno-associated viral (rAAV) vector compositions that are expressed in selected mammalian cells, such as pancreatic islets cells, and that encode one or more mammalian serpin or cytokine polypeptides having therapeutic efficacy in the amelioration, treatment and/or prevention of interleukin deficiencies, such as for example diabetes, and related ... 12/28/06 - 20060292123 - Adeno-associated virus-mediated delivery of gdnf to skeletal muscles Compositions and methods for delivering GDNF to skeletal muscles to result in a therapeutic effect are disclosed. The compositions and methods use adeno-associated virus (AAV)-based gene delivery systems. The methods are useful for treating motoneuron diseases, such as amyotrophic lateral sclerosis (ALS). ... 12/28/06 - 20060292122 - Adenoviral vectors for treating diseases Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous ... 12/28/06 - 20060292121 - Retroviral vectors including modified envelope escort protein A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein said first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion, and said modified retroviral envelope protein, prior ... 12/28/06 - 20060292120 - Compositions and methods for sirna inhibition of angiogenesis RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types ... 12/28/06 - 20060292119 - Modulation of negative immune regulators and applications for immunotherapy The invention includes compositions and methods for enhancing immunopotency of an immune cell by way of inhibiting a negative immune regulator in the cell. The present invention provides vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The present invention also provides a mechanism ... 12/28/06 - 20060292118 - Hollow nanoparticles of protein and drug using the same The subject invention is hollow nanoparticles that comprise particle-forming first proteins (e.g. hepatitis B virus surface-antigen protein), containing a bio-recognizing molecule for recognizing a specific cell, wherein at least one of the first proteins interacts with a second protein (e.g. hepatitis B virus core-antigen protein) forming a capsid structure. With ... 12/28/06 - 20060292117 - Improved raav vectors Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions that specifically target mammalian cells, such as pancreatic islets cells, that express low-density lipoprotein receptors on their cell surface. ... 12/21/06 - 20060286075 - Method and compositions for treating hepatocellular cancer A method for preventing or for treating cancer in a mammal, where the cancer cells express at least a part of an alpha fetoprotein molecule at the cell surface. The method comprises creating an immune response in the mammal to at least part of the amino acid sequence of an ... 12/21/06 - 20060286074 - Methods for immunotherapy of cancer Provided are methods of generating an immune response to an antigen specifically associated with tumor vascular endothelial cells (TVECA). The method comprises administering to an individual an expression vector encoding the TVECA. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing a TVECA and ... 12/21/06 - 20060286073 - Compositions and methods for sirna inhibition of angiogenesis RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involved angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types ... 12/21/06 - 20060286072 - techniques and compositions for treating cardiovascular disease by in vivo gene delivery Methods are provided for treating patients with cardiovascular disease, including heart disease and peripheral vascular disease. The preferred methods of the present invention involve in vivo delivery of genes, encoding angiogenic proteins or peptides, to the myocardium or to peripheral ischemic tissue, by introduction of a vector containing the gene ... 12/21/06 - 20060286071 - Therapeutic pastes for medical device coating This invention provides a high-solids therapeutic composition for coating a medical device comprising: (a) a first material which is a hydrophilic therapeutic agent; and (b) a second material which includes a hydrophobic polymer and an emulsifying surfactant, wherein the composition is in a singular stable phase. Also provided is a ... 12/14/06 - 20060280725 - Compositions and methods of treating and diagnosing hepatoma Disclosed are pharmaceutical compositions and methods of treating hepatoma by administering to patients or other populations of cells agents that selectively inhibit the uptake of glutamine by hepatocarcinoma cells, causing the concomitant apoptosis of hepatocarcinoma cells. Preferred agents target the amino acid transporter B0 (ATB0) protein for inhibition. Disclosed are ... 12/14/06 - 20060280724 - Identification of ligands that enable endocytosis, using in vivo manipulation of neuronal fibers In vivo screening is used to identify and isolate ligands that drive endocytosis (internalisation) of molecules into animal cells. These ligands can transport passenger molecules (drug or diagnostic compounds, genetic vectors, etc.) into targeted classes of cells. A population of candidate ligands, such as a phage display or combinatorial library, ... 12/07/06 - 20060275267 - Nucleic acids encoding inactive variants of human telomerase The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. Catalytically inactive variants comprising deletions or other mutations are provided. ... 12/07/06 - 20060275266 - Tripeptide of fcyriia The present invention relates, in general, to phagocytosis and phagolysosomal fusion and, in particular, to a tripeptide of FcγRIIA that mediates trafficking of targets phagocytosed via FcγRIIA to the lysosomal compartment. ... 12/07/06 - 20060275265 - Potent inhibition of influenza virus by specifically designed short interfering rna said sequences being inhibitory against influenza virus in animals including humans. The invention further includes one or more of said siRNA sequences in the form of an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a ... // - 3′ dTdTCCUAGAAUAAAGAAGCCUCUG 5′ - ... // - 5′ GGAUCUUAUUUCUUCGGAGACdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAGCC 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCGGdTdT 3′ - ... // - 3′ dTdTACUUCCUAGAAUAAAGAAG 5′ - ... // - 5′ UGAAGGAUCUUAUUUCUUCdTdT 3′ - ... 12/07/06 - 20060275264 - Novel glutamic acid decarboxylase (gad) chimera and methods of use The invention relates to a novel Glutamic Acid Decarboxylase (GAD). More specifically, novel DNA and protein sequences relating to GAD. Additionally, the invention discloses a novel composition and related methods for treating neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, epilepsy, and the like, using viral and non-viral delivery systems ... 12/07/06 - 20060275263 - Cell proliferation inhibitory proteins and polynucleotides, antisense polynucleotides to the polynucleotides, cell proliferation inhibitors using the foregoing, cancer diagnostic agents, cancer therapeutic agents and compositions for gene therapy The genes the expression of which is reduced or disappeared in immortal cells including cancer cells are isolated, their DNA sequences are determined, the genes are expressed to produce cell proliferation inhibitory proteins, and the genes and the proteins are utilized as agents for diagnosis or treatment, including the genetic ... 12/07/06 - 20060275262 - Conditionally replicating viruses and methods for cancer virotherapy The present invention provides for methods and compositions for translation of a viral vector both in vitro and in vivo. Specifically, the present invention pertains to a translational control element placed in a vector to cause a selective translation of a viral vector. In one embodiment, the present invention provides ... 12/07/06 - 20060275261 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 11/30/06 - 20060269522 - Sequence of natural or synthetic retroelements enabling nucleotide sequence insertion into a eukaryotic cell A retroviral vector that eliminates cis-acting retroviral elements, which are not useful to and may cause problems for, an integrated provirus utilizes a recombination system, such as the bacteriophage P1 cre-lox recombination system. A gene of interest and a loxP site are inserted into a long terminal repeat, which is ... 11/30/06 - 20060269521 - Avoidance of undesirable replication intermediates in plasmid propagation Disclosed herein are improved plasmid shuttle vectors, vaccines based on them, and methods related to their construction and use. Particular arrangements of functional elements of such plasmids, namely origins of replication and eukaryotic transcription/translation control elements, which give rise to generally undesirable side-products upon propagation of the plasmids in bacterial ... 11/30/06 - 20060269520 - Xiap therapy The invention features methods, compositions and kits for the treatment of degenerative disorders. ... 11/30/06 - 20060269519 - Modulation of cytokine signaling regulators and applications for immunotherapy The present invention relates to regulation of antigen presentation by cytokine signaling regulators in antigen presenting cells, such as dendritic cells. The invention provides methods of modulating antigen presentation through modulation of cytokine signaling regulators, such as SOCS (SOCS1-7, CIS), SHP (SHP-1 and SHP-2) or PIAS (PIAS1, PIAS3, PIASx and ... 11/30/06 - 20060269518 - Small interference rna gene therapy Gene expression is inhibited in a cell by introducing into the cell a lentiviral vector encoding a siRNA specific for the gene. Lentiviral vectors encoding siRNA specific for a cancer-associated gene inhibited expression of the gene and caused cell death after being introduced into cancer cells. Viral replication in HIV-infected ... 11/23/06 - 20060263334 - Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen The invention provides an isolated nucleic acid encoding a receptor, other than an immunoglobulin, wherein the receptor binds to a MUC1 tumor antigen independently of an major histocompatibility complex (MHC). The invention provides a method of activating a signaling pathway and/or killing a cancer cell using a receptor that is ... 11/23/06 - 20060263333 - Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer. ... 11/16/06 - 20060257371 - Adenoviral vectors for treating diseases Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous ... 11/16/06 - 20060257370 - Adenoviral vectors for treating diseases Adenoviral vectors, including mutant adenoviruses, that have restriction sites in the E3 region, that facilitate its partial or total deletion, or select genes contained therein, and optionally compositions and methods for substituting heterologous gene(s) in the partially or totally deleted E3 region(s), which heterologous gene(s) being operably linked to endogenous ... 11/16/06 - 20060257369 - Therapeutic regimen for treating cancer The invention provides a method for treating cancer in a human comprising (a) administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding a human TNF-α and operably linked to a promoter, wherein ... 11/16/06 - 20060257368 - Devices and methods for improved viability of cells Disclosed are devices and methods for improved viability of cells. In one embodiment of the present disclosure, a method for improved viability of cells is provided. The method includes providing a device having a body, an access port, and an insert. The body includes a selectively permeable hollow fiber membrane ... 11/16/06 - 20060257367 - Tumour-cell specific gene expression and its use in cancer therapy A polynucleotide comprising an Skp 2 promoter sequence is provided. The promoter is useful in tumour and cancer therapy, in particular in therapies that are intended to selectively kill or reduce the growth, division or viability of tumour or cancer cells compared to surrounding, non-tumour or non-cancer cells. Also provided ... 11/16/06 - 20060257366 - Chimeric glycoproteins and pseudotyped lentiviral vectors The present invention provides improved chimeric glycoproteins (GPs) and improved lentiviral vectors pseudotyped with those glycoproteins. Also provided are methods and compositions for making such glycoproteins and vectors, and improved methods of in vitro and in vivo transduction of cells with such vectors. Improved chimeric GPs encode the extracellular and ... 11/09/06 - 20060251627 - Targeted vectors for cancer immunotherapy This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided ... 11/09/06 - 20060251626 - Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors This invention relates to the use of recombinant adeno-associated virus (rAAV) vectors to transduce cardiomyocytes in vivo by infusing the rAAV into a coronary artery or coronary sinus. rAAV infection is not associated with detectable myocardial inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the stable expression ... 11/09/06 - 20060251625 - Mcv mc160 compositions and methods Provided are therapeutic compositions having anti-inflammatory activity in a human or an animal, said compositions comprising a Molluscum contagiosum virus MC160 protein or an inflammation-inhibiting peptide or polypeptide derived in amino acid sequence therefrom. Optionally, these compositions can further comprise a cell penetration peptide, such that the MC160 protein, peptide ... 11/09/06 - 20060251624 - Cells exhibiting neuronal cell progenitor characteristics and methods of making them Disclosed are cells exhibiting neuronal progenitor cell characteristics, and methods of making them from marrow adherent stem cells by regulating cellular pathways in the marrow adherent stem cells that are associated with glial transdifferentiation of the marrow adherent stem cells. ... 11/09/06 - 20060251623 - Packaged virus-like particles The present invention is related to the fields of vaccinology, immunology and medicine. The invention provides compositions and methods for enhancing immunological responses against antigens coupled or fused to virus-like particles (VLPs) packaged with immunostimulatory nucleic acids, preferably oligonucleotides containing at least one non-methylated CpG sequence and a toll-like receptor ... 11/09/06 - 20060251622 - Container for serum production and method of regenerative medicine using the same A blood storage container suitable for quick and efficient production of a large amount of serum while ensuring high safety, and a method of separating blood and a regenerative medical process using the same are provided. In a blood component separator 1 for separating collected blood into a plurality of ... 11/09/06 - 20060251621 - Ocular gene therapy Methods are provided for the delivery of a protein to the retina of a subject in need of such delivery, comprising periocularly injecting the individual with an effective amount of a viral vector comprising a protein-encoding nucleic acid. ... 11/09/06 - 20060251620 - Inducible alphaviral/orip based gene expression system The present invention relates to compositions and methods that allow the production of polypeptides and untranslated RNA molecules in host cells. More specifically, the invention provides nucleic acid molecules, expression systems, recombinant host cells, methods and kits, which enable the production and/or isolation and/or purification of polypeptides and untranslated RNA ... 11/02/06 - 20060246039 - Growth differentiation factor-7 The present invention provides antibodies that bind to the growth differentiation factor-7. ... 11/02/06 - 20060246038 - Method of treating a disorder by suicide gene therapy The present invention relates to a method of prolonging the expression of an exogenous gene in a cell transduced with the exogenous gene. The method comprises co-administration of the exogenous gene with a herpes virus gene, whereby such co-administration prolongs the expression of the exogenous gene in the transduced cell. ... 11/02/06 - 20060246037 - Neuroprotective effects of atf6 The present invention relates to methods for preventing cell death in a subject and the application of these methods for treating neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, etc. In one embodiment of the invention, a method for preventing cell death may comprise effecting overexpression of an active form ... 11/02/06 - 20060246036 - Delivery of therapeutics to the brain and spinal cord The invention provides compositions and methods for the delivery of therapeutic compounds to the brain and spinal cord. ... 10/26/06 - 20060239976 - 75k rna regulated transcription A method for altering transcription in a cell comprising an amount of active CDK9/cyclin, comprises the steps of: (a) introducing in the cell an agent which modulates the amount of active CDK9/cyclin in the cell, and thereby alters transcription in the cell, wherein the agent comprises an RNA selected from ... 10/26/06 - 20060239975 - Methods for treating cancers and restenosis with p21 The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression ... 10/26/06 - 20060239974 - Enhancing cell migration by increasing telomerase activity It has been discovered that increasing telomerase activity in cells surrounding a wound promotes wound healing. Replication capacity is enhanced, and the mobility of the epithelial cells can be increased by 3-fold or more. Particular aspects of the invention described in this disclosure include the use of agents that increase ... 10/26/06 - 20060239973 - Methods and compositions for the treatment of ocular diseases Methods and compositions for the tretament of ocular disease with a cyclin dependent kinase inhibitor are provided. ... 10/26/06 - 20060239972 - Adiponectin gene therapy Adiponectin cDNA was cloned into AAV serotypes 1, 2, and 5-based expression vectors. Virions containing these vectors were administered to the livers of rat subjects via portal vein injection. A single injection of 6×1011 virions of the vector caused a sustained and statistically significant reduction in body weight of the ... 10/26/06 - 20060239971 - Vectors for regulating gene expression The present invention pertains to vectors for regulating gene expression having at least one gene expressing cassette and at least one gene suppressing cassette, wherein the gene expression cassette encodes a polypeptide of interest, and wherein the gene suppressing cassette encodes a short interfering RNA (siRNA) molecule that reduces expression ... 10/26/06 - 20060239970 - Herpesvirus amplicon particles The invention includes methods for delivering therapeutic agents to a patient through administration of herpesvirus amplicon particles generated by a cell that stably express herpes simplex virus (HSV) immediate early 3 (IE3) gene. ... 10/26/06 - 20060239969 - Rhesus her2/neu, nucleotides encoding same, and uses thereof Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant ... 10/26/06 - 20060239968 - Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer The present invention concerns compositions comprising and methods of identification and use of targeting peptides selective for cancer tissue, particularly prostate or ovarian cancer tissue. The method may comprise identifying endogenous mimeotopes of such peptides, such as GRP78, IL-11Rα and hsp90. Antibodies against such targeting peptides or their mimeotopes may ... 10/26/06 - 20060239967 - Oncolytic virus replicating selectively in tumor cells By using a virus having a gene sequence comprising a telomerase promoter and an E1 gene (preferably a sequence comprising E1A gene, IRES sequence and E1B gene) or by using an anticancer agent comprising the virus, the virus replicates in cancer cells to thereby produce an efficient anticancer effect. ... 10/26/06 - 20060239966 - In vivo gene therapy of parkinson's disease The present invention concerns methods and compositions for gene therapy, in particular in vivo gene therapy for delivery of bioactive Neurturin for the treatment of Parkinson's Disease. In another aspect the invention relates to virus expression constructs comprising a mammalian signal peptide linked to a mature or N-terminally truncated Neurturin ... 10/19/06 - 20060233761 - Alkyl-glycoside enhanced vaccination Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject. ... 10/19/06 - 20060233760 - Splicing variant of tgf-beta2 and uses thereof An alternatively spliced form of transforming growth factor-beta2 (TGF-β2), herein denoted Δ6-TGF-β2 is disclosed. Δ6-TGF-β2 differs from TGF-β2 in the sequence of the three C-terminal exons. This novel protein is secreted, induced by cytotoxic stress in hematopoietic stem cells, and specifically blocks the enhancing effects of TGF-β2 on adult stem ... 10/19/06 - 20060233759 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 10/19/06 - 20060233758 - Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers The invention relates to conjugates comprising all or part of the amino acid sequences of at least one peptide derived from an extracellular loop of the P-170 protein. The peptide may be covalently attached to spacers which may be polyethyleneglycol (PEG), polyglycine, polylysine or any polymer chain suitable for human ... 10/19/06 - 20060233757 - Vectors with viral insulators The invention provides a vector with an isolated viral insulator or variants thereof and uses therefor, e.g., gene therapy or transgenics. ... 10/19/06 - 20060233756 - Recombinant adenoviral vectors and applications thereof The invention relates to novel recombinant adenoviruses which can be obtained from a replicating adenovirus by deleting all or part of the region of the genome of said replicating adenovirus corresponding to that located in the genome of canine adenovirus type 2 (GenBank J04368) between positions 311 and 499, the ... 10/19/06 - 20060233755 - Drug for auditory dysfunction The present invention provides a pharmaceutical preparation for hearing impairment, which is suitable for gene therapy of hearing impairment, that is, a pharmaceutical preparation for hearing impairment which comprises a virus envelope vector encapsulating a hepatocyte growth factor (HGF) gene or its plasmid as an active ingredient. Particularly, it is ... 10/19/06 - 20060233754 - Compounds promoting delivery of genes A process is provided for activating gene transfer in a cell by administering a gene transfer activating compound to the cell in conjunction with a gene transfer vector. A kit for activating gene transfer as well as process for identifying a compound that activates gene transfer are described. Use of ... 10/19/06 - 20060233753 - Use of adenoviruses mutated in the va genes for cancer treatment This invention refers to the use of an adenovirus for cancer treatment, being this adenovirus defective in its virus-associated (VA) RNAs. Said adenovirus has a mutation in the VAI or VAII gene sequence or both. This adenovirus may also have mutations in the sequences controlling expression of the VA RNAs. ... 10/12/06 - 20060228336 - Human prolyl isomerase 1 (pin 1) promoter and uses thereof PIN1 transcriptional regulatory sequences (TREs) and vectors comprising the same are provided. These include replication competent vectors and replication incompetent vectors. PIN1 TREs provide for transcriptional regulation dependent upon transcription factors that are specifically active in cancer cells. The PIN1 TREs may be used as a vehicle for introducing new ... 10/12/06 - 20060228335 - Rhesus carcino embryonic antigen, nucleotides encoding same, and uses thereof DNAs encoding rhesus monkey carcinoembryonic antigen (rhCEA) have been isolated, cloned and sequenced. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant ... 10/12/06 - 20060228334 - Modified adenoviral fiber with ablated to cellular receptors The present invention concerns a modified adenoviral fiber containing at least one mutation affecting one or more amino acid residue(s) of said adenoviral fiber interacting with at least one glycosaminoglycan and/or sialic acid-containing cellular receptor, as well as a trimer of such a modified adenoviral fiber. The present invention also ... 10/05/06 - 20060222631 - Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex A protocol for use of growth factors to stimulate neuronal cell growth and activity in trkB receptor containing cortical tissues, including the entorhinal and hippocampal cortices. The method introduces exogenous growth factor, such as BDNF, NT-4/5 and NT-3, into the EC. The method is useful in therapy of defective, diseased ... 10/05/06 - 20060222630 - Internal ribosome entry site of the labial gene for protein expression The invention describes compositions and methods for recombinant protein expression in a wide range of cell types. The compositions comprise an IRES sequence from the Drosophila labial (lab) gene, or a variant or fragment thereof, or alternatively, a homolog of a lab IRES, or a variant or fragment thereof. Methods ... 10/05/06 - 20060222629 - Compositions and methods for delivery of genetic material Methods of introducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral ... 09/28/06 - 20060216275 - Apparatus and method for pre-conditioning/fixation and treatment of disease with heat activation/release with thermoactivated drugs and gene products An apparatus and method for administering focused energy to a body using either a single energy applicator or multiple energy applicators to supply heat prior to, concurrently with and/or after delivery of a drug, gene and/or viral vector. A multi-modality treatment using a localized, focused and/or regional heating apparatus, which ... 09/28/06 - 20060216274 - Induction of immune response to antigens expressed by recombinant adeno-associated virus The present invention relates generally to immunization methods using recombinant viral vectors. In particular, the invention relates to methods and compositions for immunizing a subject with a nucleic acid molecule encoding an antigen of interest, wherein the nucleic acid molecule is delivered to the subject via a recombinant AAV virion. ... 09/28/06 - 20060216273 - Gene therapy for colorectal cancer The present invention relates to the novel use of a core 2 β-1,6-N-acetylglucosaminyltransferase (C2GnT) in the treatment of colorectal cancer. Accordingly, the present invention provides a method for treating colorectal cancer in a subject including administering to the subject a nucleic acid molecule including a sequence encoding C2GnT, wherein the ... 09/28/06 - 20060216272 - Therapeutic immunization of hiv-infected individuals The present invention provides an improved method for eliciting a therapeutic immune response in an individual infected with human immunodeficiency virus (“HIV”). The method comprises administering an adenoviral vaccine composition expressing an HIV antigen to an individual with controlled viremia. Immunization of infected individuals in this manner elicits a cellular-mediated ... 09/28/06 - 20060216271 - Methods and compositions for efficient gene transfer using transcomplementary vectors The invention includes a viral vector method and composition comprising transcomplementary replication incompetent viral vectors, preferably adenoviral vectors, which are cotransformed to a recipient cell. The two vectors complement each other and thus allow viral replication, in a synergistic combination which enhances both gene delivery and gene expression of genetic ... 09/21/06 - 20060210541 - Methods for treating and preventing vascular disease Methods for treating and/or preventing vascular disease are disclosed. The methods use gene delivery techniques to deliver nucleic acid molecules encoding anti-inflammatory cytokines to a subject. ... 09/21/06 - 20060210540 - Compositions and methods for enhancing the immunogenicity of antigens The present invention provides recombinant polypeptides comprising an N-terminal fragment of an ActA protein or LLO protein fused to an antigen or a fragment thereof, nucleotides encoding same, recombinant vectors comprising same, and immunogenic and therapeutic methods utilizing same. ... 09/21/06 - 20060210539 - Anti-angiogenic methods and compositions Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies. ... 09/21/06 - 20060210538 - Use of apotosis inhibiting compounds in degenerative neurological disorders The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used ... 09/21/06 - 20060210537 - Theileria parva dna vaccines The present invention relates to recombinant anti-Theileria parva vaccines and the administration of such vaccines to animals, advantageously bovines. Advantageously, the anti-Theileria parva vaccine encompasses a recombinant avipox virus that includes a nucleotide sequence encoding a Theileria parva gene. The invention further relates to methods of vaccinating animals, advantageously bovines, ... 09/21/06 - 20060210536 - Methods and compositions for inhibiting stat signaling pathways The invention relates to compositions and methods for modulating cell signaling mediated by signal transducers and activators of transcription (STAT). The compositions target cellular STAT3 and STAT1 protein, particularly STAT3, for degradation via the ubiquitination pathway. Thus, the STAT inhibiting agents are useful for inhibiting STAT mediated signal transduction events, ... 09/21/06 - 20060210535 - Means for regulating the expression of human isoforms of ant ARNi which can selectively inhibit expression of an isoform of ANT, characterized in that said ARNi are an ARN duplex, one of the strands being highly homologous to a fragment of ARNm coding for said isoform of ANT. ... 09/14/06 - 20060204480 - Replication competent virus or its recombinant for use in cancer therapy A method for treatment of a central nervous system cancer in an individual which includes administration, preferably peripheral administration, of a replication competent alphavirus of the Semliki Forest family, or its recombinant, to the individual. ... 09/14/06 - 20060204479 - Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors. ... 09/14/06 - 20060204478 - Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed. ... 09/14/06 - 20060204477 - Helper virus-free herpesvirus amplicon particles and uses thereof The invention features new helper virus-free methods for making herpesvirus amplicon particles that can be used in immunotherapies, including those for treating any number of infectious diseases and cancers (including chronic lymphocytic leukemia, other cancers in which blood cells become malignant, lymphomas (e.g. Hodgkin's lymphoma or non-Hodgkin's type lymphomas). Described ... 09/14/06 - 20060204476 - Treating hepatocellular carcinomas using therapeutic viruses An interferon-sensitive, replication-competent RNA virus is used to treat a mammalian subject having a hepatocellular carcinoma tumor. ... 09/14/06 - 20060204475 - Melan-a peptide analogue-virus-like-particle conjugates The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising a VLP which can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs), and particular peptides derived from MelanA ... 09/07/06 - 20060198826 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such ... 09/07/06 - 20060198825 - Reagents, methods and systems to suppress phospholamban expression The present invention relates to reagents, methods and systems to treat heart failure using small interfering RNA (siRNA) molecules targeted to phospholamban. ... 08/31/06 - 20060193833 - Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof The present invention relates to the compositions for a gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof. More specifically, the present invention provides a gene therapy of rheumatoid arthritis by preparing a recombinant vector that expresses a gene encoding an anti-angiogenic protein such ... 08/31/06 - 20060193832 - Use of the sodium iodine symporter to effect uptake of iodine The present invention relates to the use of gene therapy to introduce an iodine symporter into cell to increase iodine uptake therein. This approach has particular utility in the treatment of cancers that incapable of removing iodine. In addition, strategies are provided for reducing the export of sodium from cells ... 08/31/06 - 20060193831 - Use of pleiotrophin to promote neurogeneration The invention provides methods for promoting neuron survival in patients by administering pleiotrophin, or nucleic acids encoding pleiotrophin. Uses of the invention include promoting neuron graft survival, preventing or reducing nervous system degeneration, and restoring the nervous system, in patients suffering from, or at risk for, neurodegenerative disorders. ... 08/31/06 - 20060193830 - Raav vector compositions and methods for the treatment of choroidal neovascularization Disclosed are methods for the use of therapeutic polypeptide-encoding polynucleotides in the creation of transformed host cells and transgenic animals is disclosed. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more mammalian PEDF or anti-angiogenesis polypeptides is described. In particular, ... 08/24/06 - 20060188484 - Virus vectors and methods of making and administering the same The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors. ... 08/24/06 - 20060188483 - Virus vectors and methods of making and administering the same The present invention provides genetically-engineered parvovirus capsids and viruses designed to introduce a heterologous gene into a target cell. The parvoviruses of the invention provide a repertoire of vectors with altered antigenic properties, packaging capabilities, and/or cellular tropisms as compared with current AAV vectors. ... 08/24/06 - 20060188482 - Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal Methods for introducing recombinant adeno-associated virus (rAAV) virions into the liver of a mammal are provided. In these methods, the liver is partially or completely isolated from its blood supply, a catheter is introduced into the liver via a peripheral blood vessel, and rAAV virions are then infused through the ... 08/24/06 - 20060188481 - Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder The invention is directed to a method of prophylactically or therapeutically treating an animal for an ocular-related disorder. The method comprises administering to an eye of the animal an expression vector comprising a nucleic acid sequence encoding an adenoviral-responsive gene product. The expression vector transduces a host cell and the ... 08/24/06 - 20060188480 - Viral vectors The present invention provides a herpes virus which lacks a functional ICP34.5 encoding gene and which comprises two or more of—(i) a gene encoding a prodrug converting enzyme; (ii) a gene encoding a protein capable of causing cell to cell fusion; and (iii) a gene encoding an immunomodulatory protein. ... 08/24/06 - 20060188479 - Adenovirus vectors containing cell status-specific response elements and methods of use thereof The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using ... 08/17/06 - 20060182719 - Erbb3 binding protein compositions and methods of use A method of repressing a cell-cycle gene, which is regulated by an E2F transcription factor, in a cell, wherein the method comprises contacting the cell with a cell-cycle gene-repressing amount of ErbB3 binding protein (Ebp1); a method of inhibiting prostate cancer in a mammal, wherein the method comprises administering to ... 08/17/06 - 20060182718 - Methods and compositions comprising dna damaging agents and p53 The present invention relates to the use of tumor suppressor genes in combination with a DNA damaging agent or factor for use in killing cells, and in particular cancerous cells. A tumor suppressor gene, p53, was delivered via a recombinant adenovirus-mediated gene transfer both in vitro and in vivo, in ... 08/17/06 - 20060182717 - Vector for expressing alpha-n-acetyl-galactosaminidase and method of treating mps i by stereotactic injection into the brain of a mammal A purified nucleic acid molecule which is capable of expressing a lysosomal enzyme wherein said nucleic acid molecule comprises at least a sequence coding for said lysosomal enzyme and a promoter highly active in the brain inserted upstream from said sequence. ... 08/10/06 - 20060177423 - Composition and method for killing of tumours The present invention provides a method of treating a solid tumour in a subject, the method comprising the following steps (i) delivering to the solid tumour a composition comprising an engineered ovine atadenovirus; and (ii) administering a prodrug to the subject, wherein the engineered ovine atadenovirus comprises a promoter and ... 08/03/06 - 20060171927 - Method of inducing neuronal production in the brain and spinal cord The present invention relates to methods of inducing neuronal production in the brain, recruiting neurons to the brain, and treating a neurodegenerative condition by providing a nucleic acid construct encoding a neurotrophic factor, and injecting the nucleic acid construct intraventricularly into a subject's brain. ... 08/03/06 - 20060171926 - Gene therapy for neurometabolic disorders The disclosure pertains to methods for treating neurometabolic disorder including lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. The disclosed methods involve contacting an axonal ending of a neuron with a composition containing high titer AAV carrying a therapeutic transgene so that the AAV vector ... 08/03/06 - 20060171925 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 08/03/06 - 20060171924 - Bidirectional promoters for small rna expression The invention provides bidirectional promoters for expressing two or more short RNA sequences from a single promoter. A particular embodiment of the bidirectional promoters of the invention include: 1) a Pol III promoter that contains a TATA box, a PSE and a DSE; and 2) a Pol III promoter that ... 08/03/06 - 20060171923 - Methods of identifying modulators of human retrovirus replication This invention relates to the discovery that the transcription factors Pbx1 and HMG1 are involved in retrovirus, e.g., HIV, replication. Thus, the invention provides methods of identifying modulators of these proteins. Such modulators can be used as reagents in in vitro assays to modulate expression of retroviral sequences and may ... 08/03/06 - 20060171922 - Helper virus-free herpesvirus amplicon particles and uses thereof The invention features new helper virus-free methods for making herpes virus amplicon particles that can be used in immunotherapies, including those for treating any number of infectious diseases and cancers (including chronic lymphocytic leukemia, other cancers in which blood cells become malignant, lymphomas (e.g. Hodgkin's lymphoma or non-Hodgkin's type lymphomas). ... 07/27/06 - 20060165660 - Process for preparing purified nucleic acid and the use thereof The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable ... 07/27/06 - 20060165659 - Compositions and methods for cancer diagnosis and therapy The miR15 and miR16 micro RNA genes are located at 13q14 within a 30 kb region of loss characteristic of cells from certain cancers, such as cells from chronic lymphocytic leukemia or prostate cancer. Chronic lymphocytic leukemia or prostate cancer can be diagnosed by detecting a reduction in miR15 or ... 07/27/06 - 20060165658 - Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof Adenovirus vectors replication specific for cells expressing α-fetoprotein (AFP) and their methods of use are provided. By providing for a transcriptional initiating regulation dependent upon AFP expression, virus replication is restricted to target cells expressing AFP, particularly hepatocellular carcinoma cells. The adenovirus vectors can be used to detect and monitor ... 07/27/06 - 20060165657 - Method for delivery of cosmetic by topical application The present invention relates to compositions comprising a baculovirus vector and a pharmaceutically acceptable carrier to deliver the baculovirus vector onto or into the skin of a mammal to achieve a cosmetic effect. The present invention also provides methods of producing various cosmetic effects by administering the compositions of this ... 07/27/06 - 20060165656 - Medicinal preparation having chemotherapeutic encapsulated therein An apparatus and a method of remote control which can enable real time operation of a device in home from a terminal device at remote location through a network are provided. A first server communicates with a terminal device through the Internet and generates device control data for controlling the ... 07/20/06 - 20060159659 - Seneca valley virus based compositions and methods for treating disease The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill ... 07/13/06 - 20060153810 - Process for preparing retrovirus vector for gene therapy The present invention provides a process for preparing a retrovirus to be expressed at a high titer by specifically transferring a desired foreign gene into target cells. A pseudotyped retrovirus vector having a high titer can be prepared by transferring a DNA construction wherein a promoter, an loxP sequence, a ... 07/13/06 - 20060153809 - Recombinant trail vectors and uses thereof This invention provides a composition comprising a recombinant adeno-associated virus 2/5 (rAAV2/5) which encodes consecutive amino acids 114-281 of the amino acid sequence of the extracellular domain of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). This invention also provides a pharmaceutical composition comprising such composition and a pharmaceutically acceptable carrier. This ... 07/13/06 - 20060153808 - Cancer immunotherapy incorporating p53 A method of stimulating an immune response to a tumor in an immunocompetent subject by administering a p53 expression construct to a tumor. The construct expresses p53 in tumor cells in an amount sufficient to stimulate an immune response against the tumor. Both viral and non-viral delivery systems are contemplated. ... 07/13/06 - 20060153807 - Vector-mediated gene regulation in midbrain dopamine neurons The present invention provides compositions and methods for vector mediated gene regulation in neurons. Specifically, the present invention provides therapeutic compositions comprising viral vectors that allow for the over-expression and RNAi mediated knockdown of genes in vivo. The present invention further provides methods for treating or preventing neurodegeneration in a ... 07/13/06 - 20060153806 - Proteins involved in the regulation of energy homeostasis The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding these in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders. ... 07/13/06 - 20060153805 - Viral vectors and the use of the same for gene therapy The invention relates to viral vectors comprising nucleic acid sequences coding for single chain interleukin-12 (single chain IL-12 or scIL 12) and a costimulator protein, and to the use of said vectors for gene therapy, especially for the treatment of tumours. The invention further relates to adenoviral vectors containing nucleic ... 07/13/06 - 20060153804 - Nucleic acid coated particles Particles are provided which are suitable for delivery from a particle-mediated delivery device. The particles are obtained by precipitating a nucleic acid on inert metal carrier particles in the presence of a nucleic acid condensing agent and a metal ion chelating agent. Also described are processes for preparing the particles, ... 07/06/06 - 20060147422 - Selective induction of apoptosis to treat ocular disease The invention is directed to a method of prophylactically or therapeutically treating choroidal neovascularization, wherein the method comprises directly administering to the eye a therapeutic factor or a nucleic acid sequence that encodes a therapeutic factor, which he expressed to produce the therapeutic factor, to selectively induce apoptosis of endothelial ... 07/06/06 - 20060147421 - Methods and compositions for treating and preventing infection using human interferon regulatory factor 3 The present invention relates to IRF3 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human IRF3 protein. IRF3 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods of gene therapy using polynucleotides encoding IRF3 ... 07/06/06 - 20060147420 - Oncolytic adenovirus armed with therapeutic genes The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway. ... 07/06/06 - 20060147419 - Recombinant vaccine viruses expressing il-15 and methods of using the same The invention is directed to compositions capable of augmenting the immunogenicity of a vaccine. The composition, or adjuvant, is administered to a mammal in need thereof in sequential or concurrent combination with a vaccine antigen. In one preferred aspect, the adjuvant is provided in the form of a recombinant poxvirus ... 07/06/06 - 20060147418 - Recombinant double stranded rna phages and uses thereof The present invention provides recombinant double stranded RNA phages (rdsRP) that express dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phages are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in ... 06/29/06 - 20060140910 - Recombinant adenoviral vectors and methods of use This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 06/29/06 - 20060140909 - Method of using adenoviral vectors with increased persistence in vivo The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours ... 06/29/06 - 20060140908 - Methods for inducing an immune response via oral administration of an adenovirus The present invention provides a method for inducing an immune response to an adenovirus in a subject which has been pre-exposed to an adenovirus or adenoviral vector. The invention further provides a method for inducing a mucosal immune response to an antigen. The methods of the invention are carried out ... 06/22/06 - 20060134068 - Treatment of cancer by simultaneous inhibiton of braf and restoration or mimicry of p16ink4a activity Provided is a method for inhibiting growth of a tumor cell which comprises oncogenically activated BRAF and defective p16INK4A by inhibiting activated BRAF and restoring functional p16INK4A. Also provided is a method for sensitizing the foregoing tumor cell to cytotoxic or cytostatic effect of a chemotherapeutic agent or radiation by ... 06/22/06 - 20060134067 - Loading of cells with antigens by electroporation Methods for loading an antigen-presenting cell with one ore more antigens are disclosed. Methods for the treatment and prevention of a disease in a subject using an antigen-presenting cell that has been electroporated with a composition of one or more antigens. Composition of one or more antigens comprises one or ... 06/22/06 - 20060134066 - Localization of vectors and other agents Methods are disclosed to enhance controlled localization and/or release of an agent at an anatomical and/or physiological site where the agent is desirable. In one embodiment, the method localizes vector transfected with a gene(s) that enhances neovascularization (i.e., genes encoding angiogenic agents). In another embodiment, the method localizes genes that ... 06/22/06 - 20060134065 - Composition comprising the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors including the corresponding nucleic sequences and their therapeutic use The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The ... 06/15/06 - 20060127361 - Compositions and methods for inducing gene expression The present invention provides recombinant nucleic acid molecules encoding a chimeric transactivator protein including a DNA binding domain of a DNA binding protein and a protein domain capable of transcriptional activation. The present invention also provides recombinant viral and non-viral vectors that are able to infect and/or transfect and sustain ... 06/15/06 - 20060127360 - Multi-antigen vectors of melanoma The present invention relates to peptides, polypeptides, and nucleic acids and the use of the peptide, polypeptide or nucleic acid in preventing and/or treating cancer. In particular, the invention relates to peptides and nucleic acid sequences encoding such peptides for use in diagnosing, treating, or preventing melanoma. ... 06/15/06 - 20060127359 - Methods and compositions for heat activated gene therapy using cytolethal distending toxin The invention provides compositions and methods for gene therapy using cytolethal distending toxins (CDTs). In a preferred embodiment, a gene therapy vector according to the invention includes a gene encoding a B subunit of a CDT and an antisense oligonucleotide that inhibits a DNA repair mechanism. An inducible promoter is ... 06/15/06 - 20060127358 - Raav expression systems and methods for enhancing transduction of mammalian neural cells Disclosed are serotype-specific recombinant adeno-associated viral (rAAV) vectors, as well as viral particles and compositions comprising them, useful in the expression of neurotherapeutic agents (including neurotherapeutic peptides and polypeptides) in selected mammalian neural cells, as well as tissues and organ systems comprising them. In particular embodiments, rAAV serotype 1 and ... 06/08/06 - 20060121000 - Methods and vectors for controlling gene expression Viral vectors that include a nucleic acid encoding a therapeutic polypeptide operably linked to a heterologous destabilizing element are described. ... 06/08/06 - 20060120999 - Protein and peptide expression for passive immunity This invention relates to feeds, feed supplements, and methods for their use that provide disease controlling properties to humans, and terrestrial and aquatic animals. These methods and compositions have both acute and chronic applications. The chronic applications relate to the health of organisms that have primitive or poorly developed immune ... 06/01/06 - 20060115456 - Replication-competent adenoviral vectors This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes. ... 06/01/06 - 20060115455 - Therapeutic rnai agents for treating psoriasis The present invention provides compositions and methods suitable for delivering RNAi agents against genetic targets in skin tissues so as to treat psoriasis. ... 06/01/06 - 20060115454 - Therapeutic rnai agents for treating restenosis The present invention provides compositions and methods suitable for delivering RNAi agents against genetic targets in vascular and adjacent tissue in vivo so as to treat restenosis. ... 05/25/06 - 20060110364 - Vector-mediated delivery of polynucleotides encoding soluble vegf receptors The present invention provides vector compositions for expression of a soluble form of VEGFR3 and methods for their use in the inhibition of one or more of lymphangiogenesis, lymphatic metastasis and angiogenesis, as a therapeutic strategy for treatment of cancer. ... 05/25/06 - 20060110363 - Mutant having uracil phosphoribosyl transferase activity The invention concerns a polypeptide having a uracil phosphoribosyl transferase (UPRTase) by mutation of one or several residues of the UPRTase. The invention also concerns a nucleotide sequence coding for the UPRTase mutant, a vector for expressing the latter, a viral particle, a host cell, and a composition containing them. ... 05/25/06 - 20060110362 - Sequences upstream of the carp gene, vectors containing them and uses thereof The invention relates to novel promoter sequences derived from a portion upstream of the coding sequence of the gene for the CARP protein (Cardiac Ankyrin Repeat Protein), and which are capable of controlling the level and the specificity of expression of a transgene in vivo in cardiac muscle cells. The ... 05/25/06 - 20060110361 - Methods of making viral particles having a modified cell binding activity and uses thereof The present invention relates to a method for packaging viral particles such that one or more peptides on the surface of the article are derived from the packaging cell. By incorporating certain peptides it is possible to target viral particles to specific cell types. Such a system is of use, ... 05/18/06 - 20060104956 - Methods and compositions for inhibiting the function of polynucleotide sequences A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous ... 05/18/06 - 20060104955 - Radiation therapy by accumulation of therapeutic radionuclides in tumor-targeting bacteria The invention can be summarized as follows. According to the present invention there is provided an attenuated, tumour-targeting bacterium comprising a heterologous nucleotide sequence encoding a protein permitting the accumulation of a radionuclide within the bacterium. The heterologous nucleotide sequence may encode a sodium iodide symporter protein. The invention also ... 05/18/06 - 20060104954 - Recombinant adeno-associated virus virions for the treatment of lysosomal disorders AAV expression vectors and recombinant virions produced using these vectors, which include genes coding for enzymes defective or missing in lysosomal storage disorders, are described. These recombinant AAV virions are useful in the treatment of a variety of lysosomal storage disorders and the methods described herein provide for long-term, sustained ... 05/18/06 - 20060104953 - Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof The present invention relates to providing human primary fibroblasts with a nucleic acid of interest with, among others, the purpose to improve the taking of, for example, skin transplants, particularly, methods of transducing fibroblasts with the nucleic acid of interest by means of gene delivery vehicles, in particular chimeric recombinant ... 05/18/06 - 20060104952 - Genomic barrier to viral disease The present disclosure describes methods for the formation of a genomic barrier to viral infection as a means preventing or mediating viral disease. The formation of a genomic barrier would complement a person's immune system response based on the ability of a specific person to create a genomic environment which ... 05/18/06 - 20060104951 - Akt and regulation of ra synovial fibroblast apoptosis The administration of an Akt inhibitor in a suitable carrier to a rheumatoid arthritis synovial fibroblast affords a process for inducing rheumatoid arthritis synovial fibroblast apoptosis. The Akt inhibitor is administered either as an active molecule or as a gene sequence expressible within rheumatoid arthritis synovial fibroblast cells. The gene ... 05/18/06 - 20060104950 - Methods of tranducing genes into t cells The present invention provides methods of transducing a gene into activated T cells comprising the step of contacting a paramyxovirus vector with activated T cells. This invention also provides a method of preparing T cells transduced with a foreign gene comprising the step of contacting a paramyxovirus vector with activated ... 05/18/06 - 20060104949 - Expression control using variable intergenic sequences The present invention relates to a method of production of antibodies wherein the heavy and light chains of a particular antibody molecule are encoded by the DNA present in a dicistronic message in which the two cistrons are linked by an optimised intergenic sequence. ... 05/11/06 - 20060099188 - Tumor-specific promoter A DNA comprising a 609 bp base sequence from −559 to +50 when the first base sequence of exon 1 of the midkine gene, a human retinoic acid-responsive growth/differentiation factor was set as +1, or a DNA comprising a 251 bp base sequence from −213 to +38 when the transcription ... 05/11/06 - 20060099187 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 05/11/06 - 20060099186 - Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins Compositions and methods for systemic administration of DNA encoding bone morphogenic proteins for promotion of osteogenesis are disclosed. The compositions and methods of the invention may be utilized for fracture repair. The invention further discloses compositions and methods for systemic administration of bone morphogenetic proteins for promotion of osteogenesis. These ... 05/11/06 - 20060099185 - Methods of treating anemia using recombinant adeno-associated virus virions The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed, The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the ... 05/11/06 - 20060099184 - Methods for delivering dna to muscle cells using recombinant adeno-associated virus virions vectors The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle ... 05/11/06 - 20060099183 - Use of recombinant adeno-associated virus vector (raav) for the prevention of smooth muscle cell proliferation in a vascular graft A recombinant adeno-associated virus is used to transduce the cells of a tissue graft ex vivo. More specifically, rAAV encoding a therapeutic protein is delivered to a vascular graft to prevent smooth muscle cell proliferation or thrombosis in the graft. The cells are transfected ex vivo with the recombinant virus ... 05/11/06 - 20060099182 - Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. ... 05/11/06 - 20060099181 - Viral vectors having reduced virulence The present invention provides recombinant vaccinia virus having a deletion of the region encoding the C-terminal seven amino acids of the E3L gene product and comprising exogenous DNA. Compositions comprising the recombinant vaccinia virus and methods of use thereof are also provided. ... 05/11/06 - 20060099180 - Retroviral delivery system A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by ... 05/11/06 - 20060099179 - Glutamic acid decarboxylase (gad) based delivery system The invention provide methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain that is overstimulated in neurodegenerative diseases. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding ... 05/11/06 - 20060099178 - Novel use of adenoviruses and nucleic acids coding therefor The invention relates to the use of a virus, preferably an adenovirus, for producing a medicament. Said virus is replication-deficient in cells which do not contain YB-1 in the core and codes for an oncogene or oncogene product, especially an oncogene protein, which transactivates at least one viral gene, preferably ... 05/04/06 - 20060093585 - Compounds and methods to enhance raav transduction Agents and methods to alter rAAV transduction are provided. ... 05/04/06 - 20060093584 - Intravascular delivery of nucleic acid Disclosed is a process for providing for expression of an exogenous nucleic acid in an extravascular parenchymal cell of a mammal. The nucleic acid is inserted into a vessel of a mammal and the permeability of the vessel is increased. Increasing permeability of the vessel allows delivery of the nucleic ... 05/04/06 - 20060093583 - Targeted infusion of agents against parkinson's disease A system and method for treating Parkinson's disease by delivery of an agent within the brain. At least one image of a target region is acquired, and at least one magnetic resonance diffusion tensor imaging (MR-DTI) scan of the target region is acquired. A diffusion tensor is calculated from the ... 05/04/06 - 20060093582 - Listeria-based and llo-based vaccines This invention provides methods of treating and vaccinating against an antigen-expressing tumor and inducing an immune response against a sub-dominant epitope of antigen, comprising a fusion of an LLO fragment to the antigen or a recombinant Listeria strain expressing the antigen. The present invention also provides recombinant peptides comprising a ... 04/27/06 - 20060088504 - Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein al, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol Compositions and methods for raising the level of HDL cholesterol and apolipoprotein AI in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compositions and methods which effect the expression of a gene, LIPG, which encodes a lipase enzyme that is a ... 04/27/06 - 20060088503 - Cellular and genetic intervention to treat ventricular tachycardia A method for decreasing risk of ventricular tachycardia following myocardial infarction increases cell-to-cell coupling and/or excitability in the border zone of an infarcted region of myocardial tissue. Enhanced conduction to treat the border zone is carried out by genetically modifying myocytes in the border zone to form more gap junctions ... 04/20/06 - 20060083718 - Novel therapy for lysosomal enzyme deficiencies The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient ... 04/13/06 - 20060078542 - Gel-based delivery of recombinant adeno-associated virus vectors Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of ... 04/06/06 - 20060073120 - Ikkalpha and ikkbeta specific inhibitors A method for modulating NF-κB dependent gene transcription in a cell comprised of modulating IKKα and IKKβ protein and protein activity in the cell. The present invention also provides siRNA compositions and methods thereof for modulating NF-κB dependent gene transcription. ... 04/06/06 - 20060073119 - Methods for treating neurodegenerative disorders Vectors and methods are provided for treatment of neurodegenerative disorders by administration of anti-inflammatory cytokines, such as IL-10. Anti-inflammatory cytokines can be administered as a protein or by gene therapy, using plasmid delivery or a viral vector such as adeno-associated virus (AAV). Diseases including Parkinson's disease, Amyotrophic Lateral Sclerosis, Alzheimer's ... 03/23/06 - 20060062765 - Lentiviral vector-mediated gene transfer and uses thereof The present invention provides lentiviral vectors that are useful in human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated. ... 03/23/06 - 20060062764 - Fiber-modified adenoviral vectors for enhanced transduction of tumor cells Adenoviral vectors which effectively transduce primary tumor cells are provided. The adenoviral vectors comprise a chimeric adenovirus fiber protein which includes at least a portion of a Subgroup C adenovirus fiber shaft and at least a portion of a Subgroup B adenovirus or serotype 37 adenovirus head, wherein the head ... 03/16/06 - 20060057117 - Vascular endothelial growth factor 2 Disclosed are human VEGF-2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA(RNA) encoding such VEGF-2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides and polynucleotides may be used therapeutically for stimulating ... 03/16/06 - 20060057116 - Recombinant influenza viruses for vaccines and gene therapy The invention provides a composition useful to prepare influenza A viruses, e.g., in the absence of helper virus. ... 03/16/06 - 20060057115 - Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations ... 03/16/06 - 20060057114 - Methods of using vectors to treat metabolic disorders Isolated nucleic acid-based vectors and lentivirus vectors, and methods of using those vectors to inhibit or prevent metabolic disorders in a mammal, are provided. ... 03/16/06 - 20060057113 - Novel adenoviruses, nucleic acids coding therefor, and use thereof The present invention is related to an adenovirus expressing a first protein which is selected from the group comprising an E1B protein and an E4 protein, priorto a second protein which is selected from the group comprising an E1A protein. ... 03/09/06 - 20060051322 - Method for therapy of neurodegenerative disease of the brain A specific clinical protocol for use toward therapy of defective, diseased and damaged cholinergic neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin into, or within close proximity of, identified ... 02/23/06 - 20060039893 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 02/16/06 - 20060034805 - Aav vector compositions and methods for enhanced expression of immunoglobulins using the same Single AAV vector constructs for expression of an immunoglobulin molecule or fragment thereof and methods of making and using the same are described. The AAV vectors comprise a self-processing cleavage sequence between a first and second immunoglobulin coding sequence allowing for expression of a functional antibody molecule using a single ... 02/16/06 - 20060034804 - Adenoviral vectors having a protein ix deletion This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also ... 02/16/06 - 20060034803 - Therapeutic device for osteogenesis The object of the present invention is to provide an osteogenic treatment device having excellent bone formation ability and being capable of forming bone having a shape corresponding to a shape of site of implantation. The osteogenic treatment device of the present invention includes nucleic acid containing a base sequence ... 02/02/06 - 20060024274 - Retroviral vectors A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence. ... 02/02/06 - 20060024273 - Target cell-specific adenoviral vectors containing e3 and methods of use thereof The invention provides adenoviral vectors (preferably replication competent) comprising both an E3 sequence and at least one adenoviral gene under transcriptional control of a target cell-specific transcriptional response element. These vectors display significantly improved cytotoxicity, which is especially useful in the cancer context, in which selective destruction of target cells ... 01/26/06 - 20060018882 - Medical devices and methods for delivering compositions to cells The present invention provides medical devices and methods for delivering compositions to cells. The compositions include an artificial viral vector, and particularly, an artificial adeno-associated virus vector. Such compositions can be useful for delivering the artificial viral vector across the blood-brain barrier. ... 01/26/06 - 20060018881 - Coordinate in vivo gene expression Nucleic acids, including DNA constructs and RNA transcripts, capable of inducing coordinate expression of two to three cistrons upon direct introduction into animal tissues, are. bi- or tri-cistronic polynucleotides of this invention include those encoding and co-expressing HIV gene products, genes encoding antigens unrelated to HIV, and immunostimulatory gene products, ... 01/26/06 - 20060018880 - Methods and compositions for delivery of an enhanced response to antigenic substrates A novel immunostimulating delivery system is disclosed which provides for generation of a specific antibody response and specific T cell response to delivered antigens. According to the invention, the antigen or a nucleotide encoding the same is contained within, impregnated in or associated with a biocompatible collagen based carrier composition. ... 01/26/06 - 20060018879 - Expression vectors for treating bacterial infections The present invention is compositions and methods for producing anti-bacterial polypeptides, and for using those compositions and methods for treating diseases and conditions caused by a bacterial infection. More specifically, the compositions and methods include treating a gram-negative bacterium with a gram-positive host that produces a polypeptide effective against the ... 01/19/06 - 20060013803 - Modified dendritic cells Infection of a dendritic cell with a lentivirus impairs the dendritic cell's ability to act as an antigen presenting cell that polarizes a naïve T cell to develop along the Th1 pathway. This impairment is restored by infecting dendritic cells with lentiviruses containing vectors encoding IL-7, IL-12, and siRNA targeting ... 01/12/06 - 20060008448 - Inhibition of li expression in mammalian cells The present invention is directed toward compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. More specifically, disclosed are compositions and methods which relate to MHC Class II molecule presentation of antigenic epitopes which, under normal circumstances, would not be ... 01/05/06 - 20060002897 - Vectors for tissue-specific replication The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per ... 01/05/06 - 20060002896 - Method of generating recombinant mva The present invention relates to MVA mutants, which can be used for the generation of recombinant MVA viruses, as well as host cells, which have been infected with these mutant MVA viruses. The present invention further relates to DNA-vector constructs, and a method for the generation of recombinant MVA by ... 01/05/06 - 20060002895 - Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery The present invention generally relates to viral vectors and their use as expression vectors for transforming human cells, both in vitro and in vivo. More particularly, the present invention relates to adenoviral vectors containing propapoptotic genes and their use in cancer therapy. ... 01/05/06 - 20060002894 - Method for introducing a biological molecule using a viral envelope and composition and system therefor The object of the present invention is to provide a method of efficient delivery into a brain and central nervous system, and to provide a method of efficient delivery with a viral envelope. The present invention provides a system for introducing a biomolecule into a cell comprising A) a biomolecule; ... 01/05/06 - 20060002893 - Targeted adenovirus vectors for delivery of heterologous genes Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign ... 12/29/05 - 20050287123 - Dna vaccines encoding cea and a cd40 ligand and methods of use thereof A DNA vaccine effective for eliciting an immune response against cells that present a carcinoembryonic antigen (CEA) comprises a DNA operably encoding a CEA and a DNA operably encoding a CD40 ligand, SEQ ID NO:1 and SEQ ID NO: 2, respectively, or its homotrimer, CD40LT. The DNA vaccine can be ... 12/29/05 - 20050287122 - Aav vectors and methods The invention relates to Adeno-associated virus vectors. In particular, it relates to Adeno-associated virus vectors with modified capsid proteins and materials and methods for their preparation and use. ... 12/29/05 - 20050287121 - Methods, compositions and compound assays for inhibiting amyloid-beta protein production A method for identifying compounds that inhibit aberrant amyloid-beta precursor protein processing in cells, comprising contacting a test compound with a LIGASE polypeptide, or fragment thereof, and measuring a compound-LIGASE property related to the production of amyloid-beta peptide. Cellular assays of the method measure amyloid beta peptide levels. Therapeutic methods, ... 12/29/05 - 20050287120 - Cancer - targeted viral vectors The present invention relates to viral vectors that are targeted to cancer cells. The viral vectors of the invention are adenoviruses having a PEG-3 promoter driving the expression of the viral genes E1A and E1B. The PEG-3 promoter exhibits increased activity in malignant cells. Adenoviruses of the invention show increased ... 12/29/05 - 20050287119 - Methods and compositions for treatment of interferon-resistant tumors The present invention provides a method for the treatment of interferon resistant tumors through the use of recombinant vectors encoding interferon species. In particular it is noted that interferon species provided by recombinant vectors possesses properties not associated with the recombinantly produced interferon proteins. The present invention further provides compositions ... 12/29/05 - 20050287118 - Bacterial plasmid with immunological adjuvant function and uses thereof Plasmid adjuvant compositions and methods for enhancing an immune response to a coadministered immunogen are described. The plasmid adjuvants include a combination of cytokines and chemokines designed to elicit an enhanced immune response. Particular combinations can be provided to generate a Th1 and/or a Th2 immune response. ... 12/29/05 - 20050287117 - Vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus The present invention relates to a vaccine enhancing the protective immunity to Hepatitis C virus using plasmid DNA and recombinant adenovirus, more particularly to a vaccine consisting of Δcore-E1-E2 expressing DNA vaccine, nonstructural protein NS3 and NS4 expressing DNA vaccine, nonstructural protein NS5 expressing DNA vaccine and recombinant adenovirus vaccine, ... 12/29/05 - 20050287116 - Packaging cell line for diptheria toxin expressing non-replicating adenovirus The invention provides a packaging cell line for production of diphtheria toxin (DT) expressing, non-replicating adenovirus for use in suicide gene therapy of cancer cells, as well as production of immunotoxins. Also provided are methods for producing diphtheria toxin (DT) expressing, non-replicating adenovirus, methods for producing immunotoxins, and adenovirus and ... 12/22/05 - 20050281787 - Tumor-specific vector for gene therapy The invention relates to a vector for the gene therapeutic treatment of tumors, especially in connection with radiotherapy. Said vector is provided with a therapeutic gene in the DNA sequence thereof. The gene is controlled by the promoter for the catalytic subunit of the telomerase or by the promoter for ... 12/22/05 - 20050281786 - Aav mediated gene delivery to cochlear cells The present invention is directed to a method of transducing mammalian cochlear cells, more preferably, cochlear hair cells and support cells. The method involves the delivery of adeno-associated virus (AAV) to a target mammalian cochlear cell. The AAV comprises DNA which is exogenous to the AAV and a promoter operatively ... 12/22/05 - 20050281785 - Method of reducing side effects of cancer therapy using p53 recombinant adenovirus The present invention discloses that recombinant p53 adenovirus can ameliorate the side effects normally associated with chemotherapy and radiotherapy. Administration of recombinant p53 adenovirus is effective in reducing the side effects of cancer therapy on patients, and improving the biochemical parameters of these patients. The invention also discloses that recombinant ... 12/22/05 - 20050281784 - Methods for administering recombinant adeno-associated virus virons to humans previously exposed to adeno-associated virus The present invention provides methods for administering recombinant adeno-associated virus (rAAV) virions to a human who has preexisting antibodies to wild-type adeno-associated virus (wtAAV) due to either a previous infection with wtAAV or to a previous administration of rAAV virions. In addition, the present invention also provides methods for treating ... 12/22/05 - 20050281783 - Listeria-based epha2 vaccines The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly metastatic cancer and cancers of T cell origin, and hyperproliferative diseases involving EphA2-expressing cells. The methods of the invention entail the use of a Listeria-based EphA2 vaccine. The invention also provides pharmaceutical ... 12/22/05 - 20050281782 - Novel recombinant poxvirus composition and uses thereof The present invention provides a recombinant pox virus composition comprising a nucleic acid sequence encoding chemokines as costimulatory molecules. The present invention further provides a host cell, a host animal, and a pharmaceutical composition comprising the recombinant pox virus composition. Also provided is a method for treating or preventing a ... 12/22/05 - 20050281781 - Drug delivery product and methods The present invention provides a particulate delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload molecule and a payload trapping molecule. The invention further provides methods of making and methods of using the particulate delivery system. ... 12/15/05 - 20050276789 - Immunostimulatory oligonucleotides and uses thereof wherein X1 is C,T,G or A (preferably T or C); wherein X2 is C,T,G or A; wherein X7 is C,T,G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does ... 12/15/05 - 20050276788 - Self-containing lactobacillus strain The invention relates to a recombinant Lactobacillus strain, with limited growth and viability in the environment. More particularly, it relates to a recombinant Lactobacillus that can only survive in a medium, where well-defined medium compounds, preferably thymidine or thymine, are present. A preferred embodiment is a Lactobacillus that may only ... 12/15/05 - 20050276787 - Adeno-associated vector compositions for expression of factor viii One form of a composition has two types of recombinant adeno-associated virus. The first type encodes a portion of Factor VIII operably linked to an expression control element; and the second type encodes a different portion of Factor VIII operably linked to an expression control element. The first and second ... 12/08/05 - 20050271628 - Negative-sense rna virus vector for nerve cell Use of a negative-sense RNA virus vector has enabled transfer of nucleic acid into nerve cells. The method of this invention can be used for introducing a gene efficiently into nerve cells including the central nerve tissue in gene therapy, etc. ... 12/08/05 - 20050271627 - Calbindin-d28k protection against glucocorticoid induced cell death The present invention provides novel compositions containing a calbindin-D28k therapeutic element, which is involved in the regulation of apoptosis, and may be administered for the prevention of an abnormal apoptosis response in cells. In particular the compositions and methods of the present invention may be used for the prevention or ... 12/08/05 - 20050271626 - Use of prolactin receptor antagonists in combination with an agent that inactivates the her2/neu signaling pathway The present invention describes compositions and methods for inhibiting cell proliferation comprising a prolactin receptor antagonist and an agent that inactivates the HER2/neu signaling pathway, and methods of use thereof. ... 12/08/05 - 20050271625 - Raav-neprilysin compositions and methods of use Disclosed are methods for the use of neprilysin-encoding polynucleotides in the creation of transformed host cells and transgenic animals. In particular, the use of recombinant adeno-associated viral (rAAV) vector compositions comprising polynucleotide sequences that express one or more biologically-active mammalian neprilysin polypeptides is described. Also disclosed are medicaments and methods ... 12/08/05 - 20050271624 - Use of apoptosis inducing agents in the treatment of (auto) immune diseases The invention relates to therapies for (auto) immune diseases. Synthesis or presence of apoptotic activity in cells causing or related to (auto) immune diseases, such as synoviocytes in rheumatoid arthritis, will result in the induction of apoptosis. The invention also relates to gene-delivery vehicles, which comprise nucleic acid molecules encoding ... 12/08/05 - 20050271623 - Reduction of dermal scarring Methods and compositions for reducing or inhibiting dermal scarring by expressing p21WAF1/Cip1 in a wound site are provided. ... 12/08/05 - 20050271622 - Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof Disclosed is a recombinant human adenovirus type 5 adenovirus construct, in which a 920-946 nt sequence of ADV5 genome and a 28532-29360 nt sequence of the E3 region are deleted while a foreign cDNA fragment is reversely inserted into the deleted E3 region. A method for preparing the recombinant ADV5 ... 12/08/05 - 20050271621 - Ablated slam-dependent entry Control apparatus forcefully stops inverter and inverter when DC/DC converter is anomalously stopped. Additionally, when one of inverters is anomalously stopped while DC/DC converter is normal, control apparatus forcefully stops the other inverter. Then, when a recovery condition is satisfied after the other inverter is forcefully stopped, control apparatus recovers ... 12/08/05 - 20050271620 - Herpes simplex virus complex There is provided an HSV complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an ... 12/01/05 - 20050265975 - Method for selective inactivation of viral replication Method for screening for an antiviral agent, by determining whether a potential agent interacts with a virus or cellular component which allows or prevents preferential translation of a virus RNA compared to a host RNA under virus infection conditions; and determining whether any interaction of the agent with the component ... 12/01/05 - 20050265974 - Recombinant viral-based malaria vaccines The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are ... 12/01/05 - 20050265973 - Chimeric adenoviruses for use in cancer treatment The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index. ... 12/01/05 - 20050265972 - Treatment of diabetes with synthetic beta cells Disclosed is a method for obtaining glucose-regulated expression of active insulin in the cells of a mammalian subject. The method involves delivering into the subject a genetic construct comprising a coding sequence for a human proinsulin operably connected a promoter functional in the host cells. The construct includes a glucose ... 12/01/05 - 20050265971 - Agent for treatment of breast cancer and pancreatic cancer comprising herpes simplex virus mutant There is provided a novel therapeutic agent for pancreatic cancer, metastatic breast cancer and recurrent breast cancer in human. The present invention provides a method for treating a patient having pancreatic cancer, metastatic breast cancer or recurrent breast cancer comprising administrating to the patient a herpes simplex virus mutant where ... 12/01/05 - 20050265970 - Identification of novel factors that block programmed cell death or apoptosis by targeting jnk Methods and compositions for modulating apoptosis by acting on the c-Jun-N-terminal kinase (JNK) pathway and assays for the isolation of agents capable of modulating apoptosis, including modulators of the JNK pathway are disclosed. A method of modulating JNK pathway independent of Gadd46β is disclosed. Methods and compositions are presented for ... 11/24/05 - 20050260169 - Treatment of cancer using hsv mutant Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the γ34.5 gene in the long repeat region (RL) such that the γ34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant. ... 11/24/05 - 20050260168 - Compositions comprising viruses and methods for concentrating virus preparations A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed. ... 11/24/05 - 20050260167 - Interferon alpha and antisense k-ras rna combination gene therapy An antiproliferative effect of IFN-α gene transduction in pancreatic cancer cells. The invention relates to expression of IFN-α to effectively induce growth suppression and cell death in pancreatic cancer cells, an effect which appeared to be more prominent when compared with other types of cancers and normal cells. Another aspect ... 11/24/05 - 20050260166 - Expressional enhancers from viruses The present invention discloses that vertebrate viruses encode RNA silencing suppressors/expressional enhancers which enable them to overcome host intracellular defense responses. This has paved the way for the development of protein production systems and for production systems of (recombinant) virus particles, and of vaccines directed against vertebrate viruses. ... 11/24/05 - 20050260165 - Hs-40 enhancer-containing vector A viral expression vector having a nucleic acid which includes (1) a transcriptional start site; (2) a promoter operably linked to the transcriptional start site; and (3) an enhancer operably linked to the promoter, the enhancer comprising the DNA sequence of SEQ ID NO: 1 or the RNA equivalent thereof. ... 11/24/05 - 20050260164 - Gene regulation with aptamer and modulator complexes for gene therapy Provided is an improved method for controlling gene expression in vivo through the use of a gene switch comprising one or more aptamer sequences operably linked to or incorporated into the untranslated regions (UTRs) of a transgene or nucleotide sequence of interest. Also provided are expression vectors having aptamer sequences ... 11/24/05 - 20050260163 - Triplex hairpin ribozyme A recombinant plasmid or expression vector comprising a sequence encoding a trans-acting hairpin ribozyme or inserted RNA flanked by 5′ and 3′ self-cleavage cis-acting hairpin ribozymes, which produces a long RNA transcript that undergoes self-catalyzed cleavage at the 5′ and 3′ sides of the trans-acting ribozyme or inserted RNA. ... 11/24/05 - 20050260162 - Conditionally replicative adenovirus to target the rb and rb-related pathways The present invention involves a method of treating cancer using a mutant adenovirus that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming the cells with a wild type retinoblastoma pathway. ... 11/24/05 - 20050260161 - Method for modulating, regulating and/or stabilizing angiogenesis A method of modulating, regulating and/or stabilizing angiogenesis in a mammal in need thereof, in which the PDGF-D level or activity or both in the mammal are modulated or increased. In preferred embodiments, an active PDGF-D polypeptide, or a polynucleotide encoding an active PDGF-D is administered to the mammal, preferably ... 11/24/05 - 20050260160 - Enzyme-prodrug therapy for prosthetic joint repair The invention relates to the use of gene therapy in the treatment of aseptic loosening of orthopaedic prostheses and discloses methods of refixing such prostheses without open revision surgery. In particular, it provides adenoviral vectors and prodrugs for simultaneous, separate or sequential use in the destruction of interface tissue allowing ... 11/24/05 - 20050260159 - Intracellular interleukin-1 receptor antagonist and uses thereof Matrix metalloproteinases are major mediators of tissue destruction in various chronic inflammatory disorders. The present invention demonstrates that over-expression of intracellular isoform of IL-1 receptor antagonist confers to recipient cells resistance to signaling pathways of proinflammatory cytokines (such as tumor necrosis factor alpha and IL-1 beta) that induce matrix metalloproteinase ... 11/24/05 - 20050260158 - Human stem cell materials and methods Monocyte derived adult stem cells (MDSCs) isolated from peripheral blood of mammals are provided, along with pharmaceutical compositions containing an MDSC, kits containing a pharmaceutical composition, and methods of preparing, propagating and using MDSCs or differentiated derivatives thereof. The uses of these biological materials include methods of treating disorders or ... 11/24/05 - 20050260157 - Method and agent for treating vulnerable plaque A method and gene therapy agent for treating a vulnerable plaque associated with a blood vessel of a patient is disclosed. The method includes providing at least one gene therapy agent encoding at least one protein. The gene therapy agent is administered to a target cell population. The protein is ... 11/17/05 - 20050255089 - Aav5 nucleic acids The present invention provides an adeno-associated virus 5 (AAV5) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV5 vectors and particles. ... 11/17/05 - 20050255088 - Genetically modified tumor-targeted bacteria with reduced virulence The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The invention is also directed to Salmonella sp. containing a genetically modified msbB gene as well as an genetic modification in a biosynthetic pathway ... 11/17/05 - 20050255087 - Adeno-associated virus vectors The invention provides an isolated and purified DNA molecule comprising at least one DNA segment, a biologically active subunit or variant thereof, of a circular intermediate of adeno-associated virus, which DNA segment confers increased episomal stability, persistence or abundance of the isolated DNA molecule in a host cell. The invention ... 11/17/05 - 20050255086 - Nucleic acid silencing of huntington's disease gene The present invention is directed to small interfering RNA molecules (siRNA) targeted against a Huntington's Disease gene, and methods of using these siRNA molecules. ... 11/17/05 - 20050255085 - Prevention of recurrence and metastasis of cancer The invention provides methods of preventing and treating cancer, involving the use of attenuated, replication-com-petent, oncolytic herpes viruses. ... 11/17/05 - 20050255084 - Use of a half-transporter protein of the abcg-family for selecting cells and in gene therapy The invention relates to an isolated nucleic acid comprising a sequence encoding a half transporter protein of the ABCG-family for use in gene therapy, to the use of the isolated nucleic acid for selecting somatic mammalian cells against at least one drug transportable by the transporter protein, to vectors, cells, ... 11/10/05 - 20050249707 - Herpes virus vectors for dendritic cells An attenuated herpes virus capable of efficiently infecting a dendritic cell without preventing antigen processing occurring within the infected cell. The attenuated herpes virus and dendritic cells infected with the virus are useful immunotherapeutic methods of treating disease. ... 11/10/05 - 20050249706 - Compositions and methods for tumor-targeted delivery of effector molecules The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor ... 11/10/05 - 20050249705 - Antitumor agents with the use of hsv It is intended to provide highly safe antitumor agents which exhibit an antitumor effect on human remote tumors such as metastatic tumors too and by which an antitumor immune reaction enabling an immune therapy for cancer can be induced, tumor immunity inducers, T cell activators, dendritic cell activators, a method ... 11/03/05 - 20050244381 - Adenovirus including a gene coding for a superoxide dismutase A defective recombinant adenovirus including at least one DNA sequence coding for all or an active part of a superoxide dismutase or a derivative thereof. The therapeutical use thereof and corresponding pharmaceutical compositions are also disclosed. ... 11/03/05 - 20050244380 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 11/03/05 - 20050244379 - Immunomodulatory oligonucleotides Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides ... 11/03/05 - 20050244378 - Method for treating glaucoma A method for increasing outflow facility and reducing intraocular pressure from an eye of a subject having glaucoma includes the step of administering to the eye an amount of an ADP ribosyltransferase protein effective to reduce intraocular pressure and increase outflow facility. ... 11/03/05 - 20050244377 - Methods of treating cardiac disorders by suppressing the expression of the potassium inwardly-rectifying channel The present invention is directed toward methods for regulating biological pacemaking activity and devices used in such regulation. Such regulation can be accomplished by introducing genetic material to the heart by transfecting heart cells of the atrium or ventricle with an oligonucleotide, small interfering RNA, that silence KCNJ2, and suppress ... 11/03/05 - 20050244376 - Modified viral surface proteins for binding to extracellular matrix components A viral or non-viral vector particle having a modified viral surface protein wherein the viral surface protein is modified to include a targeting polypeptide including a binding region which binds to an extracellular matrix component. Such vector particles are useful in delivering genes encoding therapeutic agents to cells located at ... 11/03/05 - 20050244375 - Composition and method of cancer treatment The invention discloses a method for treating cancer comprising administering to a patient an effective amount of attenuated Salmonella typhimurium containing a plasmid carrying the coding sequence encoding human interleukin-2 and an oil containing a high antioxidant concentration and a method for administering the composition. ... 11/03/05 - 20050244374 - Enveloped miroorganism The invention relates to an enveloped microorganism in whose genome the following components are inserted and can be expressed: I) a nucleotide sequence that encodes a directly or indirectly, antiproliferatively or cytotoxically active expression product or a plurality of said expression products, II) a nucleotide sequence that encodes or is ... 10/27/05 - 20050238622 - Compositions and methods for treating cancer with an oncolytic viral agent The invention discloses lytic viruses as anti-neoplastic agents for specifically replicating and lysing tumor cells. According to the present invention, the agents preferably include E1A deficient adenoviral vectors, exemplified by Ad.HIL6gfp, encoding an IL-6/sIL-6R complex, HIL-6, which is able to replicate, produce cytotoxic effects, and kill tumor cells in the ... 10/20/05 - 20050232900 - Serotype of adenovirus and uses thereof Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described differ in at least capsid proteins ... 10/13/05 - 20050226850 - Treatment of non-neuronal cancer using hsv-1 variants A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment ... 10/13/05 - 20050226849 - Compositions and methods of using capsid protein from flaviviruses and pestiviruses This invention provides methods of inducing cell death with Flavivirus or Pestivirus capsid protein, such as West Nile virus (WNV) capsid protein, and functional fragments thereof. The invention also provides methods of treating patients suffering from diseases characterized by hyperproliferating cells by administering pharmaceutical compositions comprising WNV or other virus ... 10/13/05 - 20050226848 - Transcriptional regulation of gene expression by small double-stranded modulatory rna The invention provides a method for modulating gene expression by contacting a cellular system with a double-stranded ribonucleic acid molecule capable of associating with a regulatory machinery that controls transcription of one or more genes, wherein the association results in altered expression of the one or more genes. The invention ... 10/13/05 - 20050226847 - Adeno-associated virus producer system The present invention provides the use of a replication competent herpes virus which (a) lacks a functional wild-type HSV ICP27 gene; and (b) comprises an ICP27 gene encoding an ICP27 protein which allows replication of said herpes virus to occur and which has a reduced ability to inhibit RNA splicing ... 10/06/05 - 20050220768 - Materials and methods for treating ocular-related disorders The invention is directed to a method of delivering a gene product to an animal. The method comprises administering an expression vector comprising a nucleic acid sequence operably linked to a promoter and encoding a gene product, and upregulating transcription of the nucleic acid sequence in the ocular cell. The ... 10/06/05 - 20050220767 - Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral ... 10/06/05 - 20050220766 - Viral vectors and methods for producing and using the same A recombinant hybrid virus, including: (a) a deleted adenovirus vector genome comprising the adenovirus 5′ and 3′ cis-elements for viral replication and encapsidation, and further comprising a deletion in an adenovirus genomic region selected from the group consisting of: (i) the polymerase region, wherein said deletion essentially prevents the expression ... 10/06/05 - 20050220765 - Viruses with enhanced lytic potency Described is a replication competent recombinant virus, being capable to replicate and having lytic capacity in target cells, the said cell being hampered in the p53 dependent apoptosis pathway, the virus including in the genome thereof, the coding sequence of at least one restoring factor functional in restoring the p53 ... 09/29/05 - 20050214258 - Vectors for delivering viral and oncogenic inhibitors Cell transformation vectors for inhibiting HIV and tumor growth are provided. Optionally, the vectors encode RNAses such as EDN. Cells transduced by the vectors and methods of transforming cells (in vitro and in vivo) using the vectors are also provided. ... 09/29/05 - 20050214257 - Compositions and methods for controlling stem cell and tumor cell differentiation, growth, and formation The present invention relates to the use of self-assembling peptide amphiphiles to prevent tumor formation by transplanted stem cells. The present invention further relates to the use of self-assembling peptide amphiphiles to treat cancers. ... 09/29/05 - 20050214256 - Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof The present invention relates to polynucleotides encoding immunogenic HIV polypeptides. Uses of the polynucleotides in applications including immunization, generation of packaging cell lines, and production of HIV polypeptides are also described. Polynucleotides encoding antigenic HIV polypeptides are described, as are uses of these polynucleotides and polypeptide products therefrom, including formulations ... 09/22/05 - 20050208023 - Tumor treating composition and methods The invention relates to the treatment of tumors and in particular to methods and compositions for the treatment of solid vascular tumors. ... 09/22/05 - 20050208022 - Method for augmenting vision in persons suffering from photoreceptor cell degeneration The invention provides compositions and methods of treating subjects afflicted with a photoreceptor disorder. Methods for treating a subject suffering from a disorder characterized by photoreceptor cell degeneration are provided, wherein a gene encoding a photosensitive protein is introduced into a retinal cell of a subject. In one aspect of ... 09/22/05 - 20050208021 - Methods of unidirectional, site-specific integration into a genome, compositions and kits for practicing the same The subject invention provides a unidirectional site-specific integration system for integrating a nucleic acid into the genome of a target cell. The provided systems include a (1) a mutant, unidirectional site specific integrase, which can be provided by an integrase vector encoding the mutant integrase and (2) a targeting vector ... 09/22/05 - 20050208020 - Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines The inventive subject matter relates to an immunogenic composition and method of enhancing immunogenicity and protective immunity induced by any subunit or whole organism vaccine or combination of vaccines comprising administering to the subject a priming immunization preparation containing an antigen or fragment thereof, said preparation being selected from the ... 09/15/05 - 20050201986 - Cell targeting compositions and methods of using the same Drug delivery compositions and methods of delivering compounds to specific cell types are disclosed. Vaccines and methods of immunizing individuals are disclosed. Compositions for drug delivery including gene therapy and methods of treating individuals using such compositions are disclosed. ... 09/15/05 - 20050201985 - Modified adenoviral vectors for use in vaccines and gene therapy The present invention provides novel methods and means for influencing the CTL-sensitivity of antigen presenting cells (such as dendritic cells) upon viral infections. The invention provides gene delivery vehicles useful in different therapeutic settings such as vaccination and/or gene therapy. ... 09/15/05 - 20050201984 - Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars A recombinant adenoviral vector bearing exogenous genes that encode for therapeutic proteins useful in the treatment of hepatic cirrhosis and generalized fibrosis. ... 09/15/05 - 20050201983 - Engineered baculoviruses and their use Baculovirus is engineered so that the capsid displays one or more heterologous peptides or protein. Such baculovirus can be used to deliver therapeutics, and in functional genomics. ... 09/08/05 - 20050196384 - Settings for recombinant adenoviral-based vaccines The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy ... 09/08/05 - 20050196383 - Compositions and methods for the potentiation of immune responses against target antigens The present invention provides novel adjuvant systems for the potentiation of immune responses against antigenic targets. ... 09/08/05 - 20050196382 - Antiviral oligonucleotides targeting viral families Random sequence oligonucleotides that have antiviral activity are described, along with their use as antiviral agents. In many cases, the oligonucleotides are greater than 40 nucleotides in length. Also described are methods for the prophylaxis or treatment of a viral infection in a human or animal, and a method for ... 09/08/05 - 20050196381 - Lentivirus vector-based approaches for generating an immune response to hiv in humans The present invention relates to multiple novel approaches for the generation of an immune response in humans using lentivirus-based vector technology. The invention provides for the ability to mimic the efficacy of a live attenuated (LA) vaccine, without exposing the patient to the risk of disease as possible with some ... 09/01/05 - 20050191278 - Coronary artery disease treatment The invention provides a method of treating coronary artery disease in a human patient comprising directly injecting into an ischemic cardiac muscle, via multiple injections to different points of the cardiac muscle, a dose of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a replication-deficient adenoviral vector comprising a ... 09/01/05 - 20050191277 - Methods of treating various cancers using melanoma differentiation associated protein-7 This invention provides a method for reversing the cancerous phenotype of a cancer cell by introducing a nucleic acid having the melanoma differentiation associated gene (mda-7) into the cell under conditions that permit the expression of the gene so as to thereby reverse the cancerous phenotype of the cell. This ... 08/25/05 - 20050186181 - Selective precipitation of viruses The invention provides new methods for purifying and concentrating viruses. The inventors have discovered that high molecular weight proteoglycans present in retroviral stocks are co-concentrated with the retroviruses, and can inhibit retroviral transduction. The new purification and concentration methods feature treatment of virus stock with an anionic polyelectrolyte and a ... 08/25/05 - 20050186180 - Enhanced immune response to an antigen by a composition of a recominant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose ... 08/25/05 - 20050186179 - Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis Isolated polynucleotide sequences exhibiting endothelial cell specific promoter activity, novel cis regulatory elements and methods of use thereof enabling treatment of diseases characterized by aberrant neovascularization or cell growth are disclosed. ... 08/25/05 - 20050186178 - Oncolytic adenoviral vectors encoding gm-csf Selectively replicating oncolytic adenoviral vectors comprising an adenoviral packaging signal, a termination signal sequence, an E2F responsive promoter operably linked to an adenoviral coding region, a heterologous coding sequence encoding GM-CSF and a right ITR are provided. The oncolytic adenoviral vectors are useful for expressing GM-CSF in transduced cells and ... 08/18/05 - 20050180955 - Methods of treating parkinson's disease using viral vectors Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease. ... 08/11/05 - 20050175592 - Formulation of adenovirus for gene therapy The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° ... 08/11/05 - 20050175591 - Human soluble neuropilin-1 primary polyadenylation signal and uses thereof The human soluble neuropilin-1 (sNRP) polyadenylation signal (sNRP-poly(A)), situated downstream of the GT splice donor site of intron 12 of the full-length neuropilin-1 gene, also functions as the termination codon for sNRP. This 17 nucleotide sequence efficiently facilitates addition of poly(A) tails to RNAs expressed in cells. The present invention ... 08/11/05 - 20050175590 - Viral expression vectors The present invention provides nucleic acid sequences having an altered viral movement protein and 126/183 kDa replicase proteins further characterized in its ability tostabilize a transgene contained in a virus that expresses the altered movement protein. The present invention also provides viral vectors expressing the altered movement protein, cells transformed ... 08/11/05 - 20050175589 - Anti-neoplastic viral agents A viral DNA construct, and virus encoded thereby, is provided having one or more tumor specific transcription factor binding sites in place of one or more wild type transcription factor binding sites operatively positioned in the promoter region which controls expression of E1A open reading frame in the presence of ... 08/11/05 - 20050175588 - Production of a protein delivery system for in vivo therapeutic treatment Disclosed is a generalized protein delivery system that (i) contain one or more recombinant molecule(s) that are expressed on a cellular surface and (ii) incorporated and/or associated with a particle that does not require cellular entry for delivery. The recombinant protein is preferably a protein, peptide, and/or antibody. The particle ... 08/11/05 - 20050175587 - Recombinant vectors derived from adeno-associated virus expressing tam67 for gene therapy The present invention is related to a recombinant adeno associated viral construct comprising at least: a first terminal repeat of an Adeno Associated Virus a strong heterologous promoter an heterologous DNA corresponding to the gene encoding for the c-jun mutant protein TAM67, said gene being under the control of said ... 08/04/05 - 20050169892 - Adeno-associated virus materials and methods The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. ... 08/04/05 - 20050169891 - Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, ... 08/04/05 - 20050169890 - Adenovirus vectors containing cell status-specific response elements and methods of use thereof The present invention provides adenoviral vectors comprising cell status-specific transcriptional regulatory elements which confer cell status-specific transcriptional regulation on an adenoviral gene. A “cell status” is generally a reversible physiological and/or environmental state. The invention further provides compositions and host cells comprising the vectors, as well as methods of using ... 08/04/05 - 20050169889 - Immunogenic agent therapy using plasmapheresis or exchange transfusion Lowering the level of antibody or complement in the blood of a subject by plasmapheresis or exchange transfusion prior to administering an immunogenic therapeutic agent containing a foreign epitope reduces the immune response of the subject to the therapeutic agent. ... 07/28/05 - 20050163758 - Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression The present invention relates to herpes viral mutants and methods of using these viral mutants for selectively targeting tumor cells or other populations of target cells. The viral mutants of the invention are capable of selective targeting due to the use of tumor-specific and/or cell-specific promoters to drive expression of ... 07/28/05 - 20050163757 - Anti-microbial biotherapeutic agents: alternatives to conventional pharmaceutical antibiotics Novel antimicrobial agents that can serve as replacements to conventional pharmaceutical antibiotics are disclosed. The antimicrobial agents comprise conjugatively transmissible plasmids that kill targeted pathogenic bacteria, but are not harmful to donor bacteria. Two types of lethal transmissible plasmids are disclosed. One type kills recipient bacteria by unchecked (“runaway”) replication ... 07/28/05 - 20050163756 - Oral delivery of adeno-associated viral vectors A method of expressing a gene product in the gut of an animal, which comprises administering a recombinant AAV vector to the gut of the animal, wherein the vector comprises a non-AAV gene of interest ligated into an AAV vector genome. ... 07/28/05 - 20050163755 - Methods and compositions related to 1-caldesmon Embodiments of the invention include compositions and methods for the inhibition of pathogen-mediated cytopathic effects by contacting a cell with an 1-CaD polynucleotide or polypeptide. In still further embodiments, a nucleic acid encoding 1-CaD is administered to cell infected by or at risk of infection by a pathogen. Gene delivery ... 07/28/05 - 20050163754 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same Recombinant viruses comprising a heterologous DNA sequence coding for a lipase involved in lipoprotein metabolism. The invention also concerns the preparation and use in therapy of said recombinant viruses, especially for the treatment or prevention of dyslipoproteinemia-related pathologies. ... 07/28/05 - 20050163753 - Stable adenoviral vectors and methods for propagation thereof The present invention provides methods and means to increase the stability and/or the packaging capacity of recombinant adenoviruses, by overexpression of pIX in an adenoviral packaging cell, by retaining at least a part of the E1B 55K region in the recombinant adenoviral vector or by regulating pIX with a heterologous ... 07/21/05 - 20050158283 - Methods and compositions for the production of adenoviral vectors The present invention addresses the need to improve the yield of adenovirus when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of infection temperatures lower than 37° C. in a cell culture system results in improved yields of adenovirus. In addition, it ... 07/21/05 - 20050158282 - Methods and means to promote gut absorption The present invention relates to epidermal growth factor (EGF) producing lactic acid bacteria and their use to increase intestinal villi height and to promote gut absorption. In particular, the invention relates to EGF producing Lactococcus lactis and Lactobacillus casei. The organisms may be especially useful to treat Short Bowel Syndrome. ... 07/21/05 - 20050158281 - Compositions and methods for systemic nucleic acid sequence delivery The present invention provides systemic nucleic acid sequence delivery without conventional systemic administration aids (SAAs). In certain embodiments, vascular permeability agents (VPAs), such as VEGF, are used in conjunction with nucleic acid viral vectors, such as adeno-associated virus (AAV). The present invention also provides methods of treating disease by co-administration ... 07/21/05 - 20050158280 - Method of reducing angiogenesis The invention features methods of identifying a compound capable of modulating angiogenesis. Further features of the invention are methods of promoting or inhibiting angiogenesis. Methods for the diagnosis of a CD39-associated condition and for determining the prognosis of a patient diagnosed with a CD39-associated condition are also disclosed. ... 07/21/05 - 20050158279 - Negative-sense rna virus vector for nerve cell A (−)-strand RNA virus vector for transferring a gene into nerve cells which makes it possible to efficiently transfer a gene into nerve cells including the central nervous system tissues in gene therapy, etc. ... 07/21/05 - 20050158278 - Means and methods for the production of adenovirus vectors The invention relates to methods and means for the production of adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of ... 07/21/05 - 20050158277 - Method to genetate non virulent microorganisms from pathogenic ones through permanent genetic modification of their biological membrane for vaccine production Here we describe a methodology to generate non virulent microorganisms from pathogenic ones through permanent genetic modification of the physical state of their membrane (MPS). Thus, at the onset of infection, in these transformed organisms, as they infect a host (e.g. a target cell of a higher eukaryote, particularly mammals, ... 07/14/05 - 20050152878 - Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases A method of immunizing against plaque forming diseases using display technology is provided. The method utilizes novel agents, or pharmaceutical compositions for vaccination against plaque forming diseases that rely upon presentation of an antigen or epitope on a display vehicle. The method further includes agents, or pharmaceutical compositions for vaccination ... 07/14/05 - 20050152877 - Cash (caspase homologue) with death effector domain, modulators of the function of fas receptors Proteins capable of modulating or mediating the function of MORT-1 are disclosed. Also disclosed are DNA sequences encoding these proteins, the recombinant production of these proteins as well as their use. ... 07/14/05 - 20050152876 - Compositions and methods for treating female fertility The PTX3 gene or equivalent PTX3 activity is required for female fertility. Manipulation of PTX3 activity will regulate female fertility. The effects of female sterility may be ameliorated, reproductive ability may be increased or decreased as desired, female fertility may be enhanced, or combinations thereof. The need for therapies that ... 07/07/05 - 20050147593 - Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders The present invention relates to methods and compositions designed for treatment, management, or prevention of a hyperproliferative cell disease, particular cancer. The methods of the invention comprise the administration of an effective amount of a composition that targets cells expressing low molecular weight protein tyrosine kinase (“LMW-PTP”) in particular using ... 07/07/05 - 20050147592 - Methods of treating amino acid metabolic disorders using recombinant adeno-associated virus virions Methods for delivering a heterologous gene to a mammalian subject using recombinant adeno-associated virus (rAAV) virions are described. Recombinant AAV virions containing a heterologous gene encoding a metabolic protein are delivered to a mammalian subject having a metabolic disorder. The rAAV virion-delivered heterologous gene is expressed at a therapeutic level ... 07/07/05 - 20050147591 - Methods and compositions for viral enhancement of cell killing The present invention is directed to novel methods of enhancing the effectiveness of DNA damaging agents by exposing cells to viruses prior to or during exposure to the damaging agent. In certain embodiments of the invention, the DNA damaging agent is ionizing radiation, the virus is an adenovirus, and the ... 07/07/05 - 20050147590 - Immunogenic minicells and methods of use The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject. ... 07/07/05 - 20050147589 - Compositions for delivering biologically active drug and method of using the same A composition for delivering a biologically active agent to a specific site in the living body comprises microbubble-encapsulated albumin microspheres containing perfluorocarbon. The biologically active agent is preferably at least one agent selected from the group consisting of oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, oligonucleotide probes, nucleotide vectors, viral vectors, ... 06/30/05 - 20050142115 - Papilloma pseudovirus and preparation The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs ... 06/30/05 - 20050142114 - Targeted lipid-drug formulations for delivery of drugs to myeloid and lymphoid immune cells A method of preferentially delivering an active agent to an immune cell, such as a myeloid progenitor cell, a dendritic cell, a monocyte, a macrophage or a T-lymphocyte, or other cell type restricted to a functional organ system or an anatomic entity, of a mammalian subject by administering a lipid-drug ... 06/30/05 - 20050142113 - Antimicrobial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components This invention relates uses of components of plant-like metabolic pathways not including psbA or PPi phosphofructokinase and not generally operative in animals or encoded by the plastid DNA, to develop compositions that interfere with Apicomplexan growth and survival. Components of the pathways include enzymes, transit peptides and nucleotide sequences encoding ... 06/30/05 - 20050142112 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition ... 06/30/05 - 20050142111 - Method to prevent transplant rejection by stable expression of heme oxygenase-1 The present invention relates to a method for the prevention of allograft rejection in clinical transplantation. Specifically, the method of the present invention relates to the prevention of transplant arteriosclerosis and interstitial fibrosis by stable and long-term expression of HO-1 in grafts. The present invention represents a novel therapeutic approach ... 06/23/05 - 20050136036 - Methods and compositions for the treatment of neurological disease The present invention relates to a method for delivering a nucleic acid sequence encoding neuropeptide Y, or a derivative or functional fragment thereof, to a mammalian nervous system target cell. The expression of exogenous NPY, or a derivative or a functional fragment thereof in the target cell(s) provides therapeutic benefit ... 06/23/05 - 20050136035 - Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site Cell specific replication-competent viral vectors comprising a self processing peptide cleavage sequence are provided. The targeted replication-competent viral vectors include two or more co-transcribed genes under transcriptional control of the same heterologous transcriptional regulatory element (TRE), wherein at least a second gene is under translational control of a self processing ... 06/16/05 - 20050129661 - Integrative protein-dna cochleate formulations and methods for transforming cells An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, ... 06/16/05 - 20050129660 - Process of delivering a virally encapsulated polynucleotide or viral vector to a parenchymal cell via the vascular system A process for delivering a polynucleotide into a parenchymal cell in a mammal, comprising, transporting the polynucleotide into a vessel communicating with the parenchymal cell in tissue or organ of the mammal such that the polynucleotide is transfected into the parenchymal cell. More specifically, the polynucleotide consists of a viral ... 06/09/05 - 20050123517 - Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (lcmv) The present invention provides novel pseudotyped retroviral vectors that can transduce human and other cells. Vectors are provided that are packaged efficiently in packaging cells and cell lines to generate high titer recombinant virus stocks expressing novel envelope glycoproteins. The present invention further relates to compositions for gene therapy. ... 06/09/05 - 20050123516 - Methods for therapy of neurodegenerative disease of the brain A specific clinical protocol for use toward therapy of defective, diseased and damaged neurons in the mammalian brain, of particular usefulness for treatment of neurodegenerative conditions such as Parkinson's disease and Alzheimer's disease. The protocol is practiced by delivering a definite concentration of recombinant neurotrophin, such as glial cell-derived neurotrophic ... 06/09/05 - 20050123515 - Delivery system A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; a second nucleotide sequence coding for at least a part of an envelope protein and one or more other ... 06/09/05 - 20050123514 - Increased transduction using abc transporter substrates and/or inhibitors The present invention relates to improvements in the ability to transduce a retroviral vector borne nucleic acid into cells expressing ABC transporters by use of a substrate and/or inhibitor of said transporter. Compositions and kits relating to the practice of the methods are also disclosed. Methods to determine the level ... 06/09/05 - 20050123513 - Reovirus for the treatment of neoplasia Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type ... 06/09/05 - 20050123512 - Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof The present invention provides novel Interleukin-1 Receptor Antagonist-Like (IL-1ra-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IL-1ra-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, ... 06/09/05 - 20050123511 - Dna vaccine We describe vectors for use is DNA vaccination which are adapted such that nucleic acids which encode antigenic polypeptides are presented to the imune system in a folder or partially folded state to facilitate the production of antibodies to the native protein. ... 06/09/05 - 20050123510 - Use of herpesviruses, herpesvirus proteins and nucleic acids encoding the proteins to inhibit ccr5-tropic hiv-1 infection and replication It has been discovered that herpesviruses can trigger an increase in the production of HIV-suppressive chemokines, and that these chemokines block the CCR5 receptor, which is used as a co-receptor with CD4 in the CCR5-tropic forms of HIV-1 that predominate in early stage HIV-1 infection. Use of live, attenuated or ... 06/02/05 - 20050118140 - Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture The present invention concerns a method for production of an active ingredient of a drug or diagnostic agent, in which (a) MDCK cells are infected with a virus; and (b) the MDCK cells are cultured in suspension culture on a commercial scale under conditions that permit multiplication of the viruses; ... 06/02/05 - 20050118139 - Vaccine using papilloma virus e proteins delivered by viral vector Cell-mediated immune response to a papillomavirus infection can be induced by vaccination with DNA encoding papillomavirus E genes. E genes can both prevent the occurrence of papillomavirus disease, and treat disease states. Canine papillomavirus (COPV) E genes which are codon-optimized to enhance expression in host cells are also given. ... ### FreshPatents.com Support |